U.S. patent application number 15/397313 was filed with the patent office on 2017-07-27 for serum albumin binding proteins.
This patent application is currently assigned to Ablynx N.V.. The applicant listed for this patent is Ablynx N.V.. Invention is credited to BRUNO DOMBRECHT, Peter Schotte, Cedric Jozef Neotere Ververken.
Application Number | 20170210789 15/397313 |
Document ID | / |
Family ID | 46298413 |
Filed Date | 2017-07-27 |
United States Patent
Application |
20170210789 |
Kind Code |
A1 |
DOMBRECHT; BRUNO ; et
al. |
July 27, 2017 |
SERUM ALBUMIN BINDING PROTEINS
Abstract
The present invention relates to amino acid sequences that are
capable of binding to serum albumin; to proteins and polypeptides
comprising or essentially consisting of such amino acid sequences;
to nucleic acids that encode such amino acid sequences, proteins or
polypeptides; to compositions, and in particular pharmaceutical
compositions, that comprise such amino acid sequences, proteins and
polypeptides; and to uses of such amino acid sequences, proteins
and polypeptides.
Inventors: |
DOMBRECHT; BRUNO; (Heusden,
BE) ; Schotte; Peter; (De Pinte, BE) ;
Ververken; Cedric Jozef Neotere; (Merelbeke, BE) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Ablynx N.V. |
Zwijnaarde |
|
BE |
|
|
Assignee: |
Ablynx N.V.
Zwijnaarde
BE
|
Family ID: |
46298413 |
Appl. No.: |
15/397313 |
Filed: |
January 3, 2017 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14128719 |
Mar 19, 2014 |
9573992 |
|
|
PCT/EP2012/061304 |
Jun 14, 2012 |
|
|
|
15397313 |
|
|
|
|
61500464 |
Jun 23, 2011 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07K 2317/567 20130101;
C07K 2317/569 20130101; C07K 2317/92 20130101; C07K 16/32 20130101;
C07K 2317/76 20130101; C07K 2317/31 20130101; C07K 16/18 20130101;
C07K 2317/14 20130101; C07K 2317/94 20130101; C07K 16/2863
20130101; C07K 2317/22 20130101; C07K 2317/565 20130101 |
International
Class: |
C07K 16/18 20060101
C07K016/18 |
Claims
1. Polypeptide, protein, construct, compound or other chemical
entity that comprises or essentially consists of the amino acid
sequence Alb-23 (SEQ ID NO:1) or a variant of Alb-23 which is
capable of specifically binding to human serum albumin and in which
the amino acid residue at position 5 is L, the amino acid residue
at position 16 is G, the amino acid residues at positions 44 and 45
are GP, the amino acid residues at positions 74 to 76 are SKN, and
the amino acid residue at position 83 is R, and one or more (such
as one or two) other immunoglobulin single variable domains.
2. (canceled)
3. (canceled)
4. Polypeptide, protein, construct, compound or other chemical
entity according to claim 1, in which said one or more (such as one
or two) other immunoglobulin single variable domains are one or
more (such as one or two) therapeutic immunoglobulin single
variable domains.
5. (canceled)
6. (canceled)
7. Polypeptide, protein construct, compound or other chemical
entity according to claim 1, in which said one or more (such as one
or two other immunoglobulin single variable domains are
immunoglobulin single variable domains that comprise at least two
disulphide bridges.
8. Polypeptide, protein construct, compound or other chemical
entity according to claim 1, in which at least one (and up to all)
of the other immunoglobulin single variable domains is a Nanobody
of VHH Class I.
9.-13. (canceled)
Description
RELATED APPLICATIONS
[0001] This application is a continuation of U.S. provisional
application Ser. No. 14/128,719, filed Mar. 19, 2014, which is a
national stage filing under 35 U.S.C. .sctn.371 of international
application PCT/EP2012/061304, filed Jun. 14, 2012, which was
published under PCT Article 21(2) in English, and claims the
benefit under 35 U.S.C. .sctn.119(e) of U.S. provisional
application Ser. No. 61/500,464, filed Jun. 23, 2011, the
disclosures of which are incorporated by reference herein in their
entireties.
[0002] The present invention relates to amino acid sequences that
are capable of binding to serum albumin; to proteins and
polypeptides comprising or essentially consisting of such amino
acid sequences; to nucleic acids that encode such amino acid
sequences, proteins or polypeptides; to compositions, and in
particular pharmaceutical compositions, that comprise such amino
acid sequences, proteins and polypeptides; and to uses of such
amino acid sequences, proteins and polypeptides.
[0003] Other aspects, embodiments, advantages and applications of
the invention will become clear from the further description
herein.
[0004] If any terms are not specifically defined herein, these
terms have the meaning given to them in WO 2009/068627 or WO
06/122787. If any terms used herein are not specifically defined
herein or in WO 2009/068627/WO 06/122787, then they have their
usual meaning in the art, for which reference is for example made
to the standard handbooks.
[0005] Amino acid sequences that are capable of binding to human
serum albumin and uses thereof in polypeptide constructs in order
to increase the half-life of therapeutically relevant proteins and
polypeptides are known in the art.
[0006] For example, WO 04/041865 by applicant describes Nanobodies
directed against serum albumin (and in particular against human
serum albumin) that can be linked to other proteins (such as one or
more other Nanobodies directed against a desired target) in order
to increase the half-life of said protein.
[0007] The international application WO 06/122787 describes a
number of Nanobodies against (human) serum albumin. These
Nanobodies include the Nanobody called Alb-1 (SEQ ID NO: 52 in WO
06/122787) and humanized variants thereof, such as Alb-8 (SEQ ID
NO: 62 in WO 06/122787). [Nanobody.RTM. and Nanobodies.RTM. are
trademarks of Ablynx N.V.]. Again, these can be used to extend the
half-life of therapeutic proteins and polypeptide and other
therapeutic entities or moieties.
[0008] As of the date of first filing of the present application,
the use of Nanobodies against (human) serum albumin for extending
the half-life of therapeutic moieties such as Nanobodies has been
validated by means of clinical trials. For example, the safety,
tolerability, immunogenicity and pharmacokinetics (PK) of ALX-0141,
a protein construct that comprises two Nanobodies against RANK-L
and one Nanobody against human serum albumin, has been confirmed in
phase I clinical trials (data presented by Ablynx N.V. on May 27,
2011 at the Annual European Congress of Rheumatology (EULAR) in
London). Also, numerous published patent applications of Ablynx
N.V. give examples of constructs with increased half-life that
comprise one or more Nanobodies against a therapeutic target and
one or more Nanobodies against serum albumin (such as Alb-8).
Reference is for example made to WO 04/041862, WO 2006/122786, WO
2008/020079, WO 2008/142164, WO 2009/068627 and WO 2009/147248.
[0009] Although it has been established that the use of Nanobodies
against (human) serum albumin (such as those described in WO
04/041865 and WO 06/122787, and in particular the humanized
variants of Alb-1 described in WO 06/122787) provide a good and
broadly applicable methodology for extending the half-life of
Nanobodies and of other therapeutic moieties and entities, this
does not mean that the skilled person would not benefit from having
further improved Nanobodies against human serum albumin at his
disposal for this purpose.
[0010] The present invention provides such an improved Nanobody
that is directed against human serum albumin (called "Alb-23"; see
SEQ ID NO:1), as well as a number of variants of this Nanobody
(also referred to herein as "Alb-23 like sequences" or "Alb-23
variants", see SEQ ID NO's 3 to 11 for some non-limiting examples),
as well as as compounds, polypeptides and other (protein)
constructs comprising the same (as further described herein).
[0011] The advantages that the improved Nanobody of SEQ ID NO:1 and
its variants can provide over the Nanobodies described in WO
04/041865 and WO 06/122787 will become clear from the further
description herein. For example and without limitation, these
advantages may include [0012] improved stability (such as improved
thermal stability as determined by measuring the Tm); and/or [0013]
and/or improved storage stability, as for example measured in the
SEC experiment described in Example 5); and/or [0014] a reduced
tendency to form dimers under certain formulation conditions (for
example, at high concentrations in certain aqueous formulation
buffers--see again for example Example 5).
[0015] In addition, it has been found that the improved Nanobody of
SEQ ID NO:1 and its variants are particularly suited for extending
the half-life of immunoglobulin single variable domains that
contain more than one disulphide bridge, such as VHH's and
Nanobodies belonging to the "VHH-1 class" (which as further
described herein may comprise two or even three disulphide
bridges). For example and without limitation, it has been found
that polypeptides that comprise one or more therapeutic
VHH's/Nanobodies of the VHH-1 class and the Nanobody Alb-23 (or an
Alb-23 variant) may have better expression levels in certain hosts
or host cells (and/or other advantageous properties when it comes
to expression, purification and/or production/manufacture
generally) than corresponding polypeptides that contain a serum
albumin-binding Nanobody according to WO 06/122787 such as "Alb-8"
(SEQ ID NO:62 in WO 06/122787) instead of the amino acid sequence
of SEQ ID NO:1. Again, this will become clear from the further
description and the Experimental Part herein.
[0016] These and other advantages, as well as the various aspects,
embodiments, uses and applications of the invention, will become
clear from the further description herein.
[0017] It is known that immunoglobulin single variable domains such
as Nanobodies, VHH's, (single) domain antibodies, dAbs, IgNAR
domains and microbodies (as for example described in WO 00/29004)
can be expressed in a number of host cells and host organisms, such
as bacterial cells such as E. coli, yeast strains such as Pichia
and Saccharomyces, and various mammalian cells or cell lines.
Reference is for example made to EP 0 656 946 and EP 0 698 097, as
well as the various published patent applications from Ablynx N.V.,
such as for example WO 04/041862, WO 2006/122786, WO 2008/020079,
WO 2008/142164, WO 2009/068627 or WO 2009/147248.
[0018] Similarly, it is known that when one or more immunoglobulin
single variable domains that are directed against a therapeutic
target are linked to a Nanobody that is directed to (human) serum
albumin (such as those described in WO 04/041865 and WO 06/122787)
in order to provide a construct that has increased half-life (i.e.,
compared to the therapeutic domain(s) alone), that the resulting
polypeptides and constructs can also be expressed in a number of
host cells and host organisms, such as bacterial cells such as E.
coli, yeast strains such as Pichia and Saccharomyces, and various
mammalian cells or cell lines. Reference is again made to WO
04/041865, WO 06/122787, to WO 2010/056550 and to the various
published patent applications from Ablynx N.V. mentioned
herein.
[0019] It is also generally known all VHH's and Nanobodies contain
at least one disulphide bridge, between the cysteine residue at
position 22 and the cysteine residue at position 92 (numbering
according to Kabat, see the patent applications of Ablynx
N.V.).
[0020] Although most VHH's contain only this single disulphide
bridge, it is also known that some VHH's contain a total of two (or
in exceptional cases three) disulphide bridges. For example, a
class of VHH's and Nanobodies referred to as the "VHH-1 type" or
"VHH-1 class" commonly has a second disulphide bridge between a
cysteine residue at position 50 (the first amino acid residue of
CDR2) and a cysteine residue present in CDR3 (such VHH's and
Nanobodies also often have the sequence motif EREG at positions 44
to 47). Also, some VHH's derived from camels sometimes have a
disulphide bridges between a cysteine residue present in CDR1 and a
cysteine residue present in CDR3.
[0021] Some non-limiting examples of such VHH-1 type Nanobodies
(given as illustration only; other VHH-1 type sequences against
other targets can be found in some of the other patent applications
from Ablynx N.V.) are the sequences P23ILPMP37D5 (SEQ ID NO: 2490)
and P12ILPMP80F10 (SEQ ID NO: 1954) from WO 2009/068627; the
sequences PMP30A2 (SEQ ID NO:419), PMP31C5 (SEQ ID NO: 413) and
PMP30G11 (SEQ ID NO:416) from WO 2008/020079; and the sequences
RSVPMP5A2 (SEQ ID NO: 262), RSVPMP5B2 (SEQ ID NO: 263) and
RSVPMP5C3 (SEQ ID NO: 264) from WO 2009/147248.
[0022] The non-prepublished U.S. applications 61/388,172 (filed
Sep. 30, 2010 and entitled "Biological materials related to c-Met")
and U.S. 61/451,869 (filed Mar. 11, 2011 and entitled "Biological
materials related to c-Met"), both assigned to Ablynx N.V.,
describe VHH's and Nanobodies that are directed against the
therapeutic target c-Met; and some of these VHH's and Nanobodies
(such as 4E09, SEQ ID NO:26 in U.S. 61/451,869 and SEQ ID NO: 12
herein, and some of the variants of 4E09 described in in U.S.
61/451,869) also belong to the VHH-1 class.
[0023] U.S. 61/388,172 and U.S. 61/451,869 also describe that such
VHH-1 type Nanobodies can be linked to a Nanobody against human
serum albumin in order increase its half-life (the Nanobody against
human serum albumin used in U.S. 61/388,172 and U.S. 61/451,869 is
called "Alb-11" and is given in SEQ ID NO: 5 in U.S. 61/451,869.
Alb-11 has the same amino acid sequence as Alb-8, which is SEQ ID
NO: 62 in WO 06/122787). An example of such a polypeptide
comprising Alb-11 and 4E09 is given in SEQ ID NO: 9 of U.S.
61/451,869.
[0024] Although VHH's/Nanobodies of the VHH-1 type (or more
generally, VHH's/Nanobodies that contain two or three disulphide
bridges), as well as polypeptides and other protein constructs
comprising the same (including such polypeptides that further
comprise at least one Nanobody against serum albumin in order to
provide increased half-life), can be expressed in any suitable host
or host organism, it has been found that the expression levels that
are obtained for such VHH, Nanobodies, polypeptides or constructs
may be significantly low(er) than the expression levels that are
obtained for similar/comparable VHH's, Nanobodies, polypeptides or
constructs that contain VHH's or Nanobodies that do not belong to
the VHH-1 class (or more generally, that contain VHH's/Nanobodies
with only one disulphide bridge). For example and without
limitation, whereas expression levels of more than 0.8 g/l or more
(such as 1 g/l or more) can routinely be achieved in Pichia for
polypeptides that comprise Alb-8 and one or more therapeutic
Nanobodies that are not of the VHH-1 type (see again some of the
published patent applications of Ablynx N.V.), it has been found
that it is difficult to achieve expression levels of more than 0.5
g/l for polypeptides that comprise the anti-c-Met VHH-1 type
Nanobody 4E09 (SEQ ID NO:26 in U.S. 61/451,869 and SEQ ID NO: 12
herein) or a humanized variant thereof and Alb-8 (see the
Experimental Section below). Surprisingly, it has now been found
that when the Nanobody of SEQ ID NO:1 is used in such polypeptides
(i.e., instead of Alb-8), that significantly higher expression
levels can be obtained (see the Experimental Section below).
[0025] As mentioned, in a first aspect, the invention relates to an
amino acid sequence that is directed against (human) serum albumin,
which essentially consists of or is the following amino acid
sequence:
TABLE-US-00001 [SEQ ID NO: 1]
EVQLLESGGGLVQPGGSLRLSCAASGFTFRSFGMSWVRQAPGKGPEWVSS
ISGSGSDTLYADSVKGRFTISRDNSKNTLYLQMNSLRPEDTAVYYCTIGG
SLSRSSQGTLVTVSS
[0026] This amino acid sequence is also referred to herein as
"Alb-23" or the "amino acid sequence of the invention". Alb-23 is a
humanized version of the amino acid sequence "Alb-1" (SEQ ID NO: 52
from WO 06/122787, and also referred to in WO 06/122787 as
"PMP6A6").
[0027] For the sake of convenience, FIG. 1 gives an alignment of
Alb-23 with Alb-1 and the humanized versions of Alb-1 disclosed in
Table III of WO 06/122787 (called "Alb-3" to "Alb-10" in WO
06/122787, see also SEQ ID NO's: 57 to 64 of WO 06/122787). The
amino acid sequence of Alb-1 is:
TABLE-US-00002 [SEQ ID NO: 2]
AVQLVESGGGLVQPGNSLRLSCAAGFTFRSFGMSWVRQAPGKEPEWVSSI
SGSGSDTLYADSVKGRFTISRDNAKTTLYLQMNSLKPEDTAVYYCTIGGS
LSRSSQGTQVTVSS
[0028] In the above sequence, the main differences between Alb1 and
Alb-23 have been indicated in bold and underlined. These are (with
the numbering according to Kabat, see for example Tables A-5 to A-8
of WO 2008/020079; and with each letter denominating an amino acid
residue in accordance with the standard one-letter amino acid code,
for which reference is made to Table A-2 of WO 2008/020079):
position 5: V to L; position 16: N to G; positions 44 and 45: EP to
GP; positions 74 to 76: AKT to SKN; position 83: K to R.
[0029] Thus, in a further aspect, the invention relates to an amino
acid sequence that is a variant of the sequence Alb-1 (SEQ ID
NO:2), which variant comprises:
(i) the amino acid motif GP on positions 44 and 45; (ii) the amino
acid motif SKN on positions 74 to 76; (iii) a CDR1 that is the
amino acid sequence SFGMS (SEQ ID NO:29); (iv) a CDR2 that is the
amino acid sequence SISGSGSDTLYADSVKG (SEQ ID NO:30); (v) a CDR3
that is the amino acid sequence GGSLSR (SEQ ID NO:31); and that
preferably also comprises (vi) a G at position 16; and in which
preferably (but without limitation): (vii) position 83 is an R (but
may optionally also be a K; and that further comprises (i.e., in
addition to the aforementioned amino acid differences at positions
16, 44 and 45, 74 to 76 and 83, with the amino acid differences at
positions 16 and 83 being optional but preferred) between 1 and 7,
such as between 1 and 5 further "amino acid differences" (as
defined in WO 2008/020079) with the sequence given in SEQ ID NO:2,
which may for example be one or more humanizing substitutions (as
defined in WO 2008/020079; see for example again Tables A-5 to A-8)
and/or other substitutions (with non-limiting examples of such
humanizing or other substitutions being: position 1: A to E,
position 14 P to A, or position 108: Q to L).
[0030] Similarly, the invention relates to an amino acid sequence
that is a variant of the sequence Alb-23 (SEQ ID NO:1), which
variant comprises:
(i) the amino acid motif GP on positions 44 and 45; (ii) the amino
acid motif SKN on positions 74 to 76; (iii) a CDR1 that is the
amino acid sequence SFGMS (SEQ ID NO:29); (iv) a CDR2 that is the
amino acid sequence SISGSGSDTLYADSVKG (SEQ ID NO:30); (v) a CDR3
that is the amino acid sequence GGSLSR (SEQ ID NO:31); and that
preferably also comprises (vi) a G at position 16; and in which
preferably (but without limitation): (vii) position 83 is an R (but
may optionally also be a K); and that further comprises between 1
and 7, such as between 1 and 5 further "amino acid differences" (as
defined in WO 2008/020079) with the sequence given in SEQ ID NO:1,
which may for example be one or more humanizing substitutions (as
defined in WO 2008/020079; see for example again Tables A-5 to A-8)
and/or other substitutions (with non-limiting examples of such
humanizing or other substitutions being: position 1: A to E,
position 14: P to A, or position 108: Q to L).
[0031] As will be clear to the skilled person, and although (the
use of) Alb-23 is generally preferred within the context of the
present invention, the variants described in the preceding
paragraphs share with Alb-23 some of the same amino acid
substitutions (i.e., compared to Alb-1) that are characteristic of
Alb-23 (also compared to the humanized variants of Alb-1 described
in WO 06/122787), and thus are expected to provide at least some or
even all of the advantages described herein for Alb-23. For these
reasons, these variants are also referred to herein as "Alb-23-like
sequences" or "Alb-23 variants".
[0032] In one specific, but non-limiting aspect, an Alb-23 variant
is such that, when it is used in the storage stability assay
described in Example 5 (i.e., as part of a construct that further
comprises IGE045 and a 9GS linker), that the pre-peak on SE-HPLC
for the construct comprising the Alb-23 variant after 1 month
storage at 25.degree. C. (under the further conditions given in
Example 5) is less than 10%, preferably less than 5%; and/or that
the pre-peak on SE-HPLC for the construct comprising the Alb-23
variant after 1 month storage at 40.degree. C. (under the further
conditions given in Example 5) is less than 20%, preferably less
than 15%. Reference is for example made to the comparative results
in Table 8.
[0033] Some non-limiting examples of some Alb-23 like sequences are
given in SEQ ID NO's: 3 to 11. The variants of SEQ ID NO's 6 to 11
(or other Alb-23 variants with 1 to 3 amino acid residues at the
C-terminus, which may each be independently chosen from naturally
occurring amino acid residues and may for example be independently
chosen from A, G, V, L and I) may in particular be used when the
albumin-binding Nanobody is provided at the C-terminal end of the
polypeptide or protein construct. An alignment of Alb-23 with the
sequences of SEQ ID NO's: 6 to 11 is given in FIG. 2.
TABLE-US-00003 Alb-23A: [SEQ ID NO: 3]
AVQLLESGGGLVQPGGSLRLSCAASGFTFRSFGMSWVRQAPGKGPEWVSS
ISGSGSDTLYADSVKGRFTISRDNSKNTLYLQMNSLRPEDTAVYYCTIGG SLSRSSQGTLVTVSS
Alb-23B: [SEQ ID NO: 4]
AVQLLESGGGLVQPGGSLRLSCAASGFTFRSFGMSWVRQAPGKGPEWVSS
ISGSGSDTLYADSVKGRFTISRDNSKNTLYLQMNSLRPEDTAVYYCTIGG SLSRSSQGTQVTVSS
Alb-23C: [SEQ ID NO: 5]
EVQLLESGGGLVQPGGSLRLSCAASGFTFRSFGMSWVRQAPGKGPEWVSS
ISGSGSDTLYADSVKGRFTISRDNSKNTLYLQMNSLRPEDTAVYYCTIGG SLSRSSQGTQVTVSS
Alb-23D: [SEQ ID NO: 6]
EVQLLESGGGLVQPGGSLRLSCAASGFTFRSFGMSWVRQAPGKGPEWVSS
ISGSGSDTLYADSVKGRFTISRDNSKNTLYLQMNSLRPEDTAVYYCTIGG SLSRSSQGTLVTVSSA
Alb-23E: [SEQ ID NO: 7]
EVQLLESGGGLVQPGGSLRLSCAASGFTFRSFGMSWVRQAPGKGPEWVSS
ISGSGSDTLYADSVKGRFTISRDNSKNTLYLQMNSLRPEDTAVYYCTIGG
SLSRSSQGTLVTVSSAA Alb-23F: [SEQ ID NO: 8]
EVQLLESGGGLVQPGGSLRLSCAASGFTFRSFGMSWVRQAPGKGPEWVSS
ISGSGSDTLYADSVKGRFTISRDNSKNTLYLQMNSLRPEDTAVYYCTIGG
SLSRSSQGTLVTVSSAAA Alb-23G: [SEQ ID NO: 9]
EVQLLESGGGLVQPGGSLRLSCAASGFTFRSFGMSWVRQAPGKGPEWVSS
ISGSGSDTLYADSVKGRFTISRDNSKNTLYLQMNSLRPEDTAVYYCTIGG SLSRSSQGTLVTVSSG
Alb-23H: [SEQ ID NO: 10]
EVQLLESGGGLVQPGGSLRLSCAASGFTFRSFGMSWVRQAPGKGPEWVSS
ISGSGSDTLYADSVKGRFTISRDNSKNTLYLQMNSLRPEDTAVYYCTIGG
SLSRSSQGTLVTVSSGG Alb-231: [SEQ ID NO: 11]
EVQLLESGGGLVQPGGSLRLSCAASGFTFRSFGMSWVRQAPGKGPEWVSS
ISGSGSDTLYADSVKGRFTISRDNSKNTLYLQMNSLRPEDTAVYYCTIGG
SLSRSSQGTLVTVSSGGG
[0034] Thus, in one specific, but non-limiting aspect, the
invention provides proteins or polypeptides that essentially
consist of the amino acid sequence Alb-23 (or of one of the Alb-23
variants described herein).
[0035] As further described herein, the amino acid sequence Alb-23
and the further Alb-23 variants described herein can be used with
advantage as a moiety, binding unit or fusion partner in order to
increase the half-life of therapeutic moieties such as
polypeptides, proteins, compounds (including, without limitation,
small molecules) or other therapeutic entities.
[0036] Thus, in another aspect, the invention provides
polypeptides, proteins, constructs, compounds or other chemical
entities that comprise or essentially consist of the amino acid
sequence Alb-23 (or of one of the Alb-23 variants described herein)
and one or more other amino acid sequences, (binding) domains,
binding units or other moieties or chemical entities.
[0037] In particular, the invention provides polypeptides,
proteins, constructs, compounds or other chemical entities that
comprise the amino acid sequence Alb-23 (or of one of the Alb-23
variants described herein) and one or more (such as one or two)
therapeutic moieties (which may be the same or different, and may
for example be directed against the same target or to different
targets, and when they are directed to the same target may be
directed towards the same or different epitopes, parts, domains or
subunits of said target), suitably linked to each other either
directly or via one or more suitable linkers or spacers. Such
polypeptides, proteins or constructs may for example and without
limitation be a fusion protein, as further described herein.
[0038] The invention further relates to therapeutic uses of such
polypeptides, proteins, constructs or compounds and to
pharmaceutical compositions comprising such polypeptides, proteins,
constructs or compounds.
[0039] In one aspect, the at least one therapeutic moiety comprises
or essentially consists of a therapeutic protein, polypeptide,
compound, factor or other entity. In a preferred embodiment the
therapeutic moiety is directed against a desired antigen or target,
is capable of binding to a desired antigen (and in particular
capable of specifically binding to a desired antigen), and/or is
capable of interacting with a desired target. In another
embodiment, the at least one therapeutic moiety comprises or
essentially consists of a therapeutic protein or polypeptide. In a
further embodiment, the at least one therapeutic moiety comprises
or essentially consists of a binding domain or binding unit, such
as an immunoglobulin or immunoglobulin sequence (including but not
limited to a fragment of an immunoglobulin), such as an antibody or
an antibody fragment (including but not limited to an ScFv
fragment), or of another suitable protein scaffold, such as protein
A domains (such as Affibodies.TM.), tendamistat, fibronectin,
lipocalin, CTLA-4, T-cell receptors, designed ankyrin repeats,
avimers and PDZ domains (Binz et al., Nat. Biotech 2005, Vol
23:1257), and binding moieties based on DNA or RNA including but
not limited to DNA or RNA aptamers (Ulrich et al., Comb Chem High
Throughput Screen 2006 9(8):619-32).
[0040] In yet another aspect, the at least one therapeutic moiety
comprises or essentially consists of an antibody variable domain,
such as a heavy chain variable domain or a light chain variable
domain.
[0041] In a preferred aspect, the at least one therapeutic moiety
comprises or essentially consists of at least one immunoglobulin
single variable domain, such as a domain antibody, single domain
antibody, "dAb" or Nanobody (such as a VHH, a humanized VHH or a
camelized VH) or an IgNAR domain.
[0042] In a specific embodiment, the at least one therapeutic
moiety comprises or essentially consists of at least one monovalent
Nanobody or a bivalent, multivalent, bispecific or multispecific
Nanobody construct.
[0043] The polypeptides, (fusion) proteins, constructs or compounds
that comprise Alb-23 (or an Alb-23) variant and one or more
therapeutic moieties can generally be (prepared and used) as
described in the prior art cited above (such as WO 04/041865 and WO
06/122787), but with Alb-23 or an Alb-23 variant instead of the
half-life increasing moieties described in said prior art.
[0044] The polypeptides, (fusion) proteins, constructs or compounds
that comprise Alb-23 (or an Alb-23) variant and one or more
therapeutic moieties will generally and preferably have an
increased half-life, compared to the therapeutic moiety or moieties
per se.
[0045] Generally, the constructs or fusion proteins described
herein preferably have a half-life that is at least 1.5 times,
preferably at least 2 times, such as at least 5 times, for example
at least 10 times or more than 20 times, greater than the half-life
of the corresponding therapeutic moiety per se (as measured in
either in man or a suitable animal, such as mouse or cynomolgus
monkey).
[0046] Also, preferably, any such fusion protein or construct has a
half-life in man that is increased with more than 1 hour,
preferably more than 2 hours, more preferably of more than 6 hours,
such as of more than 12 hours, compared to the half-life of the
corresponding therapeutic moiety per se.
[0047] Also, preferably, any fusion protein or construct has a
half-life in man that is more than 1 hour, preferably more than 2
hours, more preferably of more than 6 hours, such as of more than
12 hours, and for example of about one day, two days, one week, two
weeks or three weeks, and preferably no more than 2 months,
although the latter may be less critical.
[0048] Half-life can generally be defined as the time taken for the
serum concentration of the polypeptide to be reduce by 50%, in
vivo, for example due to degradation of the ligand and/or clearance
or sequestration of the ligand by natural mechanisms. In
particular, half-life may be as defined in WO 2009/068627.
[0049] Methods for pharmacokinetic analysis and determination of
half-life are familiar to those skilled in the art. Details may be
found in Kenneth, A et al: Chemical Stability of Pharmaceuticals: A
Handbook for Pharmacists and in Peters et al, Pharmacokinete
analysis: A Practical Approach (1996). Reference is also made to
"Pharmacokinetics", M Gibaldi & D Perron, published by Marcel
Dekker, 2nd revised edition (1982).
[0050] As mentioned, in one aspect, the amino acid sequence Alb-23
(or of one of the Alb-23 variants described herein) can be used to
increase the half-life of (one or more) immunoglobulin single
variable domains, such as domain antibodies, single domain
antibodies, "dAb's", VHH's or Nanobodies (such as VHH's, humanized
VHH's or camelized VH's such as camelized human VH's).
[0051] In particular, as mentioned herein, the amino acid sequence
Alb-23 (or of one of the Alb-23 variants described herein) can be
used with advantage to increase the half-life of immunoglobulin
single variable domains that comprise two or more (such as two or
three) disulphide bridges, such as VHH's/Nanobodies of the VHH-1
class.
[0052] Thus, one embodiment of the invention relates to a
polypeptide, construct or fusion protein that comprises the amino
acid sequence Alb-23 (or one of the Alb-23 variants described
herein) and one or more (such as one or two) immunoglobulin single
variable domain sequences, which are suitably linked to each other,
either directly or optionally via one or more suitable linkers or
spacers. As mentioned herein, each such immunoglobulin single
variable domain present in such a polypeptide, construct or fusion
protein may independently be a domain antibody, single domain
antibody, "dAb'" or Nanobody (such as a VHH, humanized VHH or
camelized VH, such as a camelized human VH); and according to one
specific but non-limiting aspect, at least one (and up to all) of
these immunoglobulin single variable domains comprises two or three
disulphide bridges.
[0053] Preferably, each such immunoglobulin single variable domain
is a Nanobody; and according to one specific but non-limiting
aspect, at least one (and up to all) of these immunoglobulin single
variable domains is a Nanobody of the VHH-1 class.
[0054] For example and without limitation, such a construct, fusion
protein or polypeptide may comprise: [0055] one copy of Alb-23 (or
of one of the Alb-23 variants described herein) and one such
immunoglobulin single variable domain sequence; [0056] one copy of
Alb-23 (or of one of the Alb-23 variants described herein) and two
such immunoglobulin single variable domain sequences (which may be
the same or different); or even (although usually not required and
less preferred because the resulting protein is bigger) [0057] two
copies of Alb-23 (or two copies of the Alb-23 variants described
herein, which may be the same or different) and one such
immunoglobulin single variable domain sequence; [0058] two copies
of Alb-23 (or two copies of the Alb-23 variants described herein,
which may be the same or different) and two such immunoglobulin
single variable domain sequence (which may be the same or
different); [0059] one copy of Alb-23 and three such immunoglobulin
single variable domain sequence (which may be the same or
different).
[0060] Some non-limiting examples of constructs, fusion proteins or
polypeptides of the invention can be schematically represented as
follows, in which "[Alb-23]" represents Alb-23 (or of one of the
Alb-23 variants described herein), "[therapeutic moiety 1]" and
"[therapeutic moiety 2]" represent the therapeutic moieties (which
as mentioned may each independently be an immunoglobulin single
variable domain), "-" represents a suitable linker (which is
optional) and the N-terminus is on the left hand side and the
C-terminus is on the right hand side: [0061] [Alb-23]-[therapeutic
moiety 1] [0062] [therapeutic moiety 1]-[Alb-23] [0063]
[Alb-23]-[therapeutic moiety 1]-[therapeutic moiety 1] [0064]
[therapeutic moiety 1]-[therapeutic moiety 1]-[Alb-23] [0065]
[therapeutic moiety 1]-[Alb-23]-[therapeutic moiety 1] [0066]
[Alb-23]-[therapeutic moiety 1]-[therapeutic moiety 2] [0067]
[therapeutic moiety 1]-[therapeutic moiety 2]-[Alb-23] [0068]
[therapeutic moiety 1]-[Alb-23]-[therapeutic moiety 2]
[0069] When two or more different therapeutic moieties (such as two
or more different immunoglobulin single variable domains) are
present in the constructs or polypeptides of the invention, they
may be the same or different, and when they are different they may
be directed towards the same target (for example, to the same or
different parts, domains, subunits or epitopes of said target) or
to different targets.
[0070] Thus, in another aspect, the invention relates to a
multispecific (and in particular bispecific) Nanobody construct
that comprises Alb-23 (or of one of the Alb-23 variants described
herein) and at least one other Nanobody (such as one or two other
Nanobodies, which may be the same or different), in which said at
least one other Nanobody is preferably directed against a desired
target (which is preferably a therapeutic target) and/or another
Nanobody that useful or suitable for therapeutic, prophylactic
and/or diagnostic purposes. Again, Alb-23 and the other Nanobodies
may be suitably linked to each other either directly or optionally
via one or more suitable linkers or spacers, and according to one
specific but non-limiting aspect at least one (and up to all) of
the other Nanobodies may be of the VHH-1 class.
[0071] For a general description of multivalent and multispecific
polypeptides containing one or more Nanobodies and their
preparation, reference is also made to Conrath et al., J. Biol.
Chem., Vol. 276, 10. 7346-7350, 2001; Muyldermans, Reviews in
Molecular Biotechnology 74 (2001), 277-302; as well as to for
example WO 96/34103, WO 99/23221, WO 04/041862, WO 2006/122786, WO
2008/020079, WO 2008/142164 or WO 2009/068627.
[0072] Some other examples of some specific multispecific and/or
multivalent polypeptide of the invention can be found in the
applications by Ablynx N.V. mentioned herein. In particular, for a
general description of multivalent and multispecific constructs
comprising at least one Nanobody against a serum protein for
increasing the half-life, of nucleic acids encoding the same, of
compositions comprising the same, of the preparation of the
aforementioned, and of uses of the aforementioned, reference is
made to the International applications WO 04/041865 and WO
06/122787 mentioned above (Alb-23 and the Alb-23 variants described
herein can generally be used analogously to the half-life extending
Nanobodies described therein such as Alb-8), as well as to the
general description and specific examples of such constructs given
in WO 04/041862, WO 2006/122786, WO 2008/020079, WO 2008/142164 or
WO 2009/068627.
[0073] In one non-limiting embodiment, the one or more other
Nanobodies present in such a polypeptide or protein construct may
be directed against c-Met, and may in particular be Type I
Nanobodies directed against c-Met. Some non-limiting examples of
Nanobodies against c-Met that may be present in such a polypeptide
or protein construct may for example be found in the
non-prepublished US applications U.S. 61/388,172 and U.S.
61/451,869 mentioned herein.
[0074] One particularly preferred Type I Nanobody against c-Met
that may be present in such a multivalent and/or multispecific
polypeptide (next to Alb-23 or an Alb-23 variant) is 4E09 (SEQ ID
NO:26 in U.S. 61/451,869 and SEQ ID NO: 12 herein) or variant
thereof. Such a variant of 4E09 may generally be as described in
U.S. 61/451,869 (and will generally have at least 80%, such as at
least 85%, for example at least 90% or more such as 95% or more
sequence identity with 4E09) and is preferably such that (i) it
competes with 4E09 for binding to c-Met (in a suitable binding
assay, such as the alphascreen assay described in Example 7, but
using 4E09 instead of HGF as used in Example 7); and/or (ii) it
binds to the same epitope on c-Met as 4E09; and/or (iii)
cross-blocks (as defined in WO 2009/068627) the binding of 4E09 to
c-Met. Such a variant of 4E09 may for example be a humanized and/or
sequence-optimized variant of 4E09 (as further described in U.S.
61/451,869). Some preferred, but non-limiting examples of variants
of 4E09 that could be present in such proteins or polypeptides are
the following, which are also described in U.S. 61/451,869: 04E09
(L49S); 04E09 (C50S/C100bG); 04E09 (C22A/C92S); A00790067=4E09
(Q108L); A00790068=4E09 (A74S, K83R, Q108L); A00790069=4E09 (A74S,
K83R, G88A, Q108L) and A00790105=4E09 (E1D, A74S, K83R, G88A,
Q108L), of which the latter is especially preferred. The amino acid
sequences of 4E09 and these variants are given in SEQ ID NO's: 12
to 19.
[0075] Thus, in one specific but non-limiting aspect, the invention
relates to a polypeptide or protein construct that comprises or
essentially consists of Alb-23 (preferred) or an Alb-23 variant (as
described herein), which is suitably linked (either directly or via
one or more suitable linkers) to one or two Nanobodies against
c-Met. As mentioned, according to a specific but non-limiting
aspect, said one or two Nanobodies against c-Met comprise two
disulphide bridges (i.e. are of "Class I").
[0076] In particular, the invention relates to a polypeptide or
protein construct that comprises or essentially consists of Alb-23
(preferred) or an Alb-23 variant (as described herein), which is
suitably linked (either directly or via one or more suitable
linkers) to one or two (and preferably only one) Nanobodies against
c-Met, which are 4E09 (SEQ ID NO 12) or a variant of 4E09 (as
described herein and in U.S. 61/451,869), and preferably a
humanized or sequence optimized variant of 4E09 and more preferably
A00790105 (SEQ ID NO: 19).
[0077] Some specific but non-limiting examples of such proteins and
polypeptides are the constructs Alb23-9GS-4E09, 4E09-9GS-Alb23,
Alb23-9GS-A00790105, A00790105-9GS-Alb23, Alb23-35GS-4E09,
4E09-35GS-Alb23, Alb23-35GS-A00790105, A00790105-35GS-Alb23, and
A00790105-35GS-A00790105-35GS-Alb23. The sequences of these are
given in SEQ ID NO's: 20 to 28, respectively. Of these, the
construct A00790105-9GS-Alb23 (SEQ ID NO: 23) is particularly
preferred, and thus one aspect of the invention also relates to a
polypeptide that has at least 80%, such as at least 85%, for
example at least 90%, such as at least 95% or more sequence
identity with the polypeptide of SEQ ID NO: 23.
[0078] The invention also relates to nucleotide sequences or
nucleic acids that encode amino acid sequences, fusion proteins and
constructs described herein. The invention further includes genetic
constructs that include the foregoing nucleotide sequences or
nucleic acids and one or more elements for genetic constructs known
per se. The genetic construct may be in the form of a plasmid or
vector. Again, such constructs can be generally as described in the
published patent applications of Ablynx N.V., such as for example
WO 04/041862, WO 2006/122786, WO 2008/020079, WO 2008/142164 or WO
2009/068627.
[0079] The invention also relates to hosts or host cells that
contain such nucleotide sequences or nucleic acids, and/or that
express (or are capable of expressing), the amino acid sequences,
fusion proteins and constructs described herein. Again, such host
cells can be generally as described in the published patent
applications of Ablynx N.V., such as for example WO 04/041862, WO
2006/122786, WO 2008/020079, WO 2008/142164 or WO 2009/068627.
[0080] The invention also relates to a method for preparing an
amino acid sequence, fusion protein or construct as described
herein, which method comprises cultivating or maintaining a host
cell as described herein under conditions such that said host cell
produces or expresses an amino acid sequence, fusion protein or
construct as described herein, and optionally further comprises
isolating the amino acid sequence, fusion protein or construct so
produced. Again, such methods can be performed as generally
described in the published patent applications of Ablynx N.V., such
as for example WO 04/041862, WO 2006/122786, WO 2008/020079, WO
2008/142164 or WO 2009/068627.
[0081] The invention also relates to a pharmaceutical composition
that comprises at least one amino acid sequence, fusion protein or
construct as described herein, and optionally at least one
pharmaceutically acceptable carrier, diluent or excipient. Such
preparations, carriers, excipients and diluents may generally be as
described in the published patent applications of Ablynx N.V., such
as for example WO 04/041862, WO 2006/122786, WO 2008/020079, WO
2008/142164 or WO 2009/068627.
[0082] However, since the amino acid sequences, fusion proteins or
constructs described herein have an increased half-life, they are
preferably administered to the circulation. As such, they can be
administered in any suitable manner that allows the amino acid
sequences, fusion proteins or constructs to enter the circulation,
such as intravenously, via injection or infusion, or in any other
suitable manner (including oral administration, subcutaneous
administration, intramuscular administration, administration
through the skin, intranasal administration, administration via the
lungs, etc.) that allows the amino acid sequences, fusion proteins
or constructs to enter the circulation. Suitable methods and routes
of administration will be clear to the skilled person, again for
example also from the teaching of the published patent applications
of Ablynx N.V., such as for example WO 04/041862, WO 2006/122786,
WO 2008/020079, WO 2008/142164 or WO 2009/068627.
[0083] Thus, in another aspect, the invention relates to a method
for the prevention and/or treatment of at least one disease or
disorder that can be prevented or treated by the use of a fusion
protein or construct as described herein, which method comprises
administering, to a subject in need thereof, a pharmaceutically
active amount of a fusion protein or construct of the invention,
and/or of a pharmaceutical composition comprising the same. The
diseases and disorders that can be prevented or treated by the use
of a fusion protein or construct as described herein will generally
be the same as the diseases and disorders that can be prevented or
treated by the use of the therapeutic moiety that is present in the
fusion protein or construct of the invention.
[0084] In the context of the present invention, the term
"prevention and/or treatment" not only comprises preventing and/or
treating the disease, but also generally comprises preventing the
onset of the disease, slowing or reversing the progress of disease,
preventing or slowing the onset of one or more symptoms associated
with the disease, reducing and/or alleviating one or more symptoms
associated with the disease, reducing the severity and/or the
duration of the disease and/or of any symptoms associated therewith
and/or preventing a further increase in the severity of the disease
and/or of any symptoms associated therewith, preventing, reducing
or reversing any physiological damage caused by the disease, and
generally any pharmacological action that is beneficial to the
patient being treated.
[0085] The subject to be treated may be any warm-blooded animal,
but is in particular a mammal, and more in particular a human
being. As will be clear to the skilled person, the subject to be
treated will in particular be a person suffering from, or at risk
from, the diseases and disorders mentioned herein.
[0086] In another embodiment, the invention relates to a method for
immunotherapy, and in particular for passive immunotherapy, which
method comprises administering, to a subject suffering from or at
risk of the diseases and disorders mentioned herein, a
pharmaceutically active amount of a fusion protein or construct of
the invention, and/or of a pharmaceutical composition comprising
the same.
[0087] The fusion protein or construct and/or the compositions
comprising the same are administered according to a regime of
treatment that is suitable for preventing and/or treating the
disease or disorder to be prevented or treated. The clinician will
generally be able to determine a suitable treatment regimen,
depending on factors such as the disease or disorder to be
prevented or treated, the severity of the disease to be treated
and/or the severity of the symptoms thereof, the specific
polypeptide of the invention to be used, the specific route of
administration and pharmaceutical formulation or composition to be
used, the age, gender, weight, diet, general condition of the
patient, and similar factors well known to the clinician.
[0088] Generally, the treatment regimen will comprise the
administration of one or more fusion proteins or constructs of the
invention, or of one or more compositions comprising the same, in
one or more pharmaceutically effective amounts or doses. The
specific amount(s) or doses to be administered can be determined by
the clinician, again based on the factors cited above.
[0089] Generally, for the prevention and/or treatment of the
diseases and disorders mentioned herein and depending on the
specific disease or disorder to be treated, the potency and/or the
half-life of the specific fusion proteins or constructs to be used,
the specific route of administration and the specific
pharmaceutical formulation or composition used, the Nanobodies and
polypeptides of the invention will generally be administered in an
amount between 1 gram and 0.01 microgram per kg body weight per
day, preferably between 0.1 gram and 0.1 microgram per kg body
weight per day, such as about 1, 10, 100 or 1000 microgram per kg
body weight per day, either continuously (e.g., by infusion), as a
single daily dose or as multiple divided doses during the day. The
clinician will generally be able to determine a suitable daily
dose, depending on the factors mentioned herein. It will also be
clear that in specific cases, the clinician may choose to deviate
from these amounts, for example on the basis of the factors cited
above and his expert judgment. Generally, some guidance on the
amounts to be administered can be obtained from the amounts usually
administered for comparable conventional antibodies or antibody
fragments against the same target administered via essentially the
same route, taking into account however differences in
affinity/avidity, efficacy, biodistribution, half-life and similar
factors well known to the skilled person.
[0090] Usually, in the above method, a single polypeptide of the
invention will be used. It is however within the scope of the
invention to use two or more polypeptides of the invention in
combination.
[0091] The polypeptides of the invention may also be used in
combination with one or more further pharmaceutically active
compounds or principles, i.e., as a combined treatment regimen,
which may or may not lead to a synergistic effect. Again, the
clinician will be able to select such further compounds or
principles, as well as a suitable combined treatment regimen, based
on the factors cited above and his expert judgement.
[0092] In particular, the polypeptides of the invention may be used
in combination with other pharmaceutically active compounds or
principles that are or can be used for the prevention and/or
treatment of the diseases and disorders that can be prevented or
treated with the fusion proteins or constructs of the invention,
and as a result of which a synergistic effect may or may not be
obtained.
[0093] The effectiveness of the treatment regimen used according to
the invention may be determined and/or followed in any manner known
per se for the disease or disorder involved, as will be clear to
the clinician. The clinician will also be able, where appropriate
and or a case-by-case basis, to change or modify a particular
treatment regimen, so as to achieve the desired therapeutic effect,
to avoid, limit or reduce unwanted side-effects, and/or to achieve
an appropriate balance between achieving the desired therapeutic
effect on the one hand and avoiding, limiting or reducing undesired
side effects on the other hand.
[0094] Generally, the treatment regimen will be followed until the
desired therapeutic effect is achieved and/or for as long as the
desired therapeutic effect is to be maintained. Again, this can be
determined by the clinician.
[0095] The subject to be treated may be any warm-blooded animal, in
particular a mammal, and more in particular a human being. As will
be clear to the skilled person, the subject to be treated will in
particular be a person suffering from, or at risk from, the
diseases and disorders mentioned herein.
[0096] Other aspects, embodiments, advantages and applications of
the invention will become clear from the further description
herein.
[0097] The invention will now be further illustrated by means of
the non-limiting Experimental Part and Figures, in which:
[0098] FIG. 1 is an alignment of Alb-23 (SEQ ID NO: 1) with Alb-1
and the various humanized variants thereof described in WO
06/122787;
[0099] FIG. 2 is an alignment of Alb-23 (SEQ ID NO: 1) with some of
the Alb-23 variants described herein;
[0100] FIG. 3 shows the various sequences referred to in the
present specification;
[0101] FIG. 4 shows an expression profile using SDS-PAGE analysis
of A007900009 produced by Pichia clones with a low (L=1) and high
(H=more than 1) copy number (CN) of the expression cassette.
[0102] FIG. 5 shows an expression profile using SDS-PAGE analysis
of A007900171 produced by Pichia clones with a low (L=1) and high
(H=more than 1) copy number (CN) of the expression cassette.
[0103] FIG. 6 shows an expression profile using SDS-PAGE analysis
of A007900057 and A007900058 produced by Pichia clones with a low
(L=1) and high (H=more than 1) copy number (CN) of the expression
cassette.
[0104] FIG. 7 shows an expression profile using SDS-PAGE analysis
of A007901219 variant produced by Pichia clones with a low (L=1)
and high (H=more than 1) copy number (CN) of the expression
cassette.
[0105] FIG. 8 shows SDS-Page analysis (non-reducing conditions) of
end of induction fermentation samples of Pichia pastoris
expressions of A00700171 and A00701219. 5 .mu.L cell free medium is
loaded onto the gel (Lane 1-4). Lanes 5 to 7 contain a control
Nanobody loaded in different amounts. Left lane contains the
molecular weight marker.
EXPERIMENTAL PART
Example 1: Expression Profile of 4E09 in Combination with Alb11 or
Alb23
[0106] Table 1 gives an overview of the formats based on the
anti-c-Met 4E09 VHH1 Nanobody building block (SEQ ID NO:12) in
combination with Alb11 and Alb23. The different Nanobodies were
cloned into the pPiczalpha expression vector and transformed in
Pichia pastoris X-33 strain (commercially available expression
system from Invitrogen/RCT). Clones were selected on zeocin
containing plates and a qPCR was performed to rank the clones
according to their copy numbers. Expression levels were compared
between low and high copy number clones in shake flask experiments.
An inverse correlation between expression level and copy numbers
was observed for Alb11 containing formats (FIGS. 4 and 5). In
contrast, a positive correlation between expression level and copy
numbers was observed with Nanobody formats containing the Alb23
Nanobody (FIGS. 6 and 7).
TABLE-US-00004 TABLE 1 Overview of 5 formats of the VHH1 4E09
Nanobody building block or sequence optimized version fused via a
9GS or 35GS linker to the Alb11 or Alb23 Nanobody building block.
Format Construct SEQ ID NO: A007900009 4E09-9GS-ALB11-Flag3-His6 39
A007900057 4E09-9GS-ALB23 21 A007900058 4E09-35GS-ALB23 25
A007900171 A00790105-9GS-Alb11 40 A007901219 A00790105-9GS-Alb23
23
Example 2: Fermentation Yield of 4E09 in Combination with Alb11 or
Alb23
[0107] Expression of the A007900171 (4E9 sequence
optimized-9GS-Alb11) and A007901219 (4E9 sequence
optimized-9GS-Alb23) Nanobody.RTM. was evaluated using Pichia
pastoris X33 as host organism. Both the AOX promoter (MeOH
inducible promoter) and GAP promoter (constitutive induced
promoter) were evaluated.
[0108] A complex, peptone based medium was used for the
fermentation processes. For the fermentations with the X33 clone
using the AOX promoter, MeOH was used for expression of the
Nanobody. In short, this process can be divided in 3 phases: a
batch phase, a glycerol fed batch and a MeOH induction phase.
During the batch and glycerol fed batch phase, biomass was build up
to approx. 40% (wet weight per volume). Then a MeOH adaptation and
induction phase was started during which the Nanobody.RTM. was
expressed and secreted into the medium.
[0109] For the fermentations with the X33 clone using the GAP
promoter, glucose was used to induce expression of the
Nanobody.RTM.. This process can also be divided in 3 phases: a
batch phase on glycerol, a glucose fed batch using a high feed rate
to build-up biomass to approx. 40% (wet weight per volume) and a
second glucose fed batch phase at a lower feed rate to further
induce expression/secretion of the Nanobody.RTM..
[0110] All Fermentations were carried out at 2 L fermenter scale
using Sartorius equipment (Biostat.RTM. Aplus, Biostat.RTM. Bplus
and Biostat.RTM. Bplus twin controllers, 2 L Univessel.RTM.
reactors, control via MFCSwin software). During fermentations the
following parameters were monitored/steered: DO (dissolved oxygen),
pH, foaming, biomass (OD.sub.600 for E. coli and Wet Cell Weight
(WCW) for Pichia pastoris), expression level and quality of the
product. The DO was typical 30% and controlled via a stirring
cascade, and further compensated by addition of pure oxygen on a
need basis. The pH was monitored via a pH electrode and adjusted
via ammonia additions via a base pump. Off line pH measurements
were done to check pH electrode functioning following
autoclaving.
[0111] Table 2 gives an overview of the fermentation runs performed
for expression of A007900171 and A007901219 using Pichia pastoris
as host organism.
[0112] FIG. 8 shows the SDS-Page analysis (non-reducing conditions)
of the end of induction samples of the different fermentations with
Pichia pastoris.
[0113] In Table 3 an overview of the different Pichia pastoris
fermentations with their respective parameter settings,
fermentation characteristics, and the estimated expression yield of
the end of induction samples based on SDS-Page analysis, is
shown.
[0114] The titer and purity of the produced Nanobody.RTM. at end of
fermentation was determined via a small scale protA clean-up
procedure followed by RP-HPLC analysis. In short, sample
preparation is based on protA affinity chromatography which
purifies the Nanobody.RTM. from the medium. The protein
concentration of the elution fraction is determined using UV
spectrophotometry and is followed by Reversed Phase High
Performance Liquid Chromatography (RP-HPLC) allowing determination
of product titer and product purity/heterogeneity. Table 4
summarizes the RPC results.
TABLE-US-00005 TABLE 2 Overview of the fermentation runs performed
for expression of A007900171 and A007901219 using P. pastoris as
host organism Fed-batch Induction Fermentation ID Construct Strain
Promoter Fed-batch feed rate Induction feed rate A1/110511
A007901219 X33 AOX 60% glycerol + 21.6 g/h l 100% MeOH 3.16 g/h l
Alb23 10% peptone A1/110518 A007900171 X33 AOX 60% glycerol + 21.6
g/h l 100% MeOH 3.16 g/h l Alb11 10% peptone A2/110511 A007901219
X33 GAP 25% glucose + 50.8 g/h l 50% glucose 6 g/h l Alb23 5%
peptone A4/110511 A007900171 X33 GAP 25% glucose + 50.8 g/h l 50%
glucose 6 g/h l Alb11 5% peptone
TABLE-US-00006 TABLE 3 Overview of the different A007900035
fermentations with Pichia pastoris and their respective expression
yield in clarified medium at end of fermentation determined via
SDS-Page analysis. WCW Expression yield Fermentation Induction at
end of (mg/L clarified Expression yield ID Construct Strain
Promoter time induction (g/L) medium) (mg/L broth) A1/110511
A007901219 X33 AOX 95 hrs 420 g/L -500 mg/L -290 mg/L Alb23
A1/110518 A007900171 X33 AOX 92 hrs 423 g/L -200 mg/L -115 mg/L
Alb11 A2/110511 A007901219 X33 GAP 91 hrs 421 g/L -350 mg/L -203
mg/L Alb23 A4/110511 A007900171 X33 GAP 93 hrs 374 g/L -100 mg/L
-63 mg/L Alb11
TABLE-US-00007 TABLE 4 Overview of the total yield determined via
OD.sub.280 and RPC analysis after a ProtA clean-up step, % main
peak and the intact monomeric yield. All yields are expressed in
mg/L cell free medium. Total Yield via Total Yield via Intact yield
via RPC OD.sub.290 after ProtA RPC analysis after % Main peak
analysis after ProtA Ferm. ID Construct Promoter clean-up ProtA
clean-up (RPC analysis) clean-up A1/110511 A007901219 AOX 820 mg/L
670 mg/L 68.7% 460 mg/L Alb23 A1/110518 A007900171 AOX 250 mg/L 200
mg/L 88.0% 170 mg/L Alb11 A2/110511 A007901219 GAP 340 mg/L 290
mg/L 79.0% 230 mg/L Alb23 A4/110511 A007900171 GAP 180 mg/L 150
mg/L 86.0% 130 mg/L Alb11
Example 3: Purification of A007900171 and A007901219
[0115] Both A007900171 and A007901219 molecules were purified
according to the scheme shown in Table 5:
TABLE-US-00008 TABLE 5 Overview of purification steps. Process step
Description Aim Step 1: Centrifugation and TFF Clarification of the
Clarification microfiltration (0.2 .mu.m fermentation broth
Hydrosart Sartocon slice cassette, Sartorius) Step 2: HCIC (MEP
Hypercel Capture product Capture step with elution at pH 3.5 + from
the medium neutralization with 25 mM and removal Tris pH 8.5) +
buffer of impurities exchange* (Sephadex G25 to 25 mM Tris buffer
pH 8.5) Step 3: AIEX (POROS 50HQ or Q Removal of product
Intermediate Sepharose HP) in 25 mM related variants step Tris pH
8.5 and impurities Step 4: Polish OGP treatment for LPS Removal of
LPS step removal + SEC (Superdex 75) and product related variants
and impurities *Only for A007901219
Example 4: Comparison of Properties of Alb-1, Alb-8 (=Alb-11) and
Alb-23
[0116] Various properties of Alb-1, Alb-8 and Alb-23 were
determined and compared. The results are shown in Table 6.
[0117] Also, for a side-by-side comparison of the tendency of Alb-8
and Alb-23 to form dimers, dimerization kinetics for monovalent
Alb-8 (Ea=73.0 kcal/mol) and Alb-23 (Ea=50.8 kcal/mol) at various
temperatures in PBS buffer were calculated from an Arrhenius plot.
The results are shown in Table 7, and show that for Alb-11, the
kinetics start to increase from room temperature upwards, in
particular when compared to Alb-23.
TABLE-US-00009 TABLE 6 Comparison of some of the properties of
Alb-1, Alb-8 and Alb-23. ALB1 ALB23 ALB8 K.sub.D (nM) Human SA 1.8
2.7 4.5 Cyno SA 1.9 3.0 4.6 Murine SA 17.3 16.5 68.8 Tm (.degree.
C.) TSA 64.5 69.0 61.6 DSC 65.6 71.7 65.9 Reversibility of DSC @
0.3 mg/ml & 64 92 16 unfolding (%) Tm + 5.degree. C.
Dimerization (%) 3w @ 37.degree. C. & 20 mg/ml 2 17 12w @
37.degree. C. & 20 mg/ml 6 9 44 Humanization % FR identity 86.5
93.3 91.0
TABLE-US-00010 TABLE 7 Side-by-side comparison of dimerization
kinetics of monovalent ALB8/ALB11 and ALB23 over a broad
concentration range, as calculated from an Arrhenius plot (max.
predicted % dimers after 3 years at the indicated concentration in
PBS buffer and indicated temperature). 10 mg/ml 25 mg/ml 50 mg/ml
Conc. (mg/ml) ALB11 ALB23 ALB11 ALB23 ALB11 ALB23 Temp (.degree.
C.) % dimers % dimers % dimers % dimers % dimers % dimers 5 0.00
0.03 0.01 0.09 0.02 0.17 10 0.04 0.15 0.09 0.37 0.18 0.74 15 0.31
0.63 0.77 1.60 1.50 3.20 20 2.50 2.70 6.30 6.60 12.50 13.30 25
19.00 10.60 47.50 26.60 95.10 53.20 30 >100 41.60 >100
>100 >100 >100
Example 5: Storage Stability of Constructs Comprising Alb-23
Compared to Alb-11
[0118] To compare the storage stability of bispecific constructs
comprising Alb-8 and Alb-23, respectively, two bispecific Nanobody
constructs comprising the same Nanobody against IgE (IGE045, SEQ ID
NO:43) linked to Alb-23 (IGE045-9GS-ALB23; SEQ ID NO: 41) and
Alb-11 (IGE045-9GS-ALB11; SEQ ID NO: 42) were prepared, formulated
in D-PBS buffer at a concentration of 50 mg/ml and stored in
plastic PCR tubes in the dark for 1 month at different
temperatures. After that, the amount of pre-peak (corresponding to
dimer formation) was determined and compared using SE-HPLC. The
SE-HPLC analysis was performed using aBioSep SEC-2000 column
(Phenomenex) and D-PBS as running buffer at a flow rate of 0.2
ml/min. 10 .mu.g material was injected and data was analysed using
Chromeleon software. The results are shown in Table 8.
[0119] In a similar experiment, the storage stability of two
trivalent bispecific constructs were compared (at a concentration
of 50 mg/ml in 20 mM His buffer, pH6.5, 8% sucrose). The constructs
were OX40L079 (SEQ ID NO:44), a trivalent bispecific Nanobody
construct comprising Alb-11 and two Nanobodies against OX40L (see
SEQ ID NO:229 of PCT/EP2010/069606 of Ablynx N.V., filed on 14,
Dec. 2010) and OX40L089 (SEQ ID NO:45), a corresponding construct
comprising the same two Nanobodies against OX40L, but with Alb-23
instead of Alb-11. The results are also shown in Table 8A.
TABLE-US-00011 TABLE 8A Comparative storage stability of Alb-23 and
Alb-11 constructs (% Pre peak on SE-HPLC after storage for the
indicated storage period at the indicated temperatures) Albumin
Storage Temperature (.degree. C.) Construct binder period 4 5 25 40
IGE045-9GS-ALB23 Alb-23 1 month -- 0.0 3.7 7.6 (SEQ ID NO: 41)
IGE045-9GS-ALB11 Alb-11 1 month -- 0.0 11.7 30.3 (SEQ ID NO: 42)
OX40L079 Alb-11 2 weeks 0.4 -- 1.4 25 (SEQ ID NO: 44) OX40L089
Alb-23 2 weeks 0.3 -- 1.4 13 (SEQ ID NO: 45)
[0120] In another experiment, the fermentation yield storage
stability of four different Nanobody constructs against c-Met
(A007901222/SEQ ID NO: 46; A007901256/SEQ ID NO: 47; A007901259/SEQ
ID NO: 48 and A007901260/SEQ ID NO: 49) was compared. Of these
constructs, A007901222 contains the Alb-23 albumin-binding Nanobody
(invention) as well as a "VHH-1 type" anti-c-Met Nanobody
(4E09--see again the U.S. applications 61/388,172 and U.S.
61/451,869 referred to above) whereas the other constructs (used as
comparative references) contain the Alb-11 albumin-binding Nanobody
and anti c-Met Nanobodies which are not of the VHH-1 type. For a
more detailed description of the constructs used, reference is made
to the co-pending U.S. application Ser. No. 13/435,567 (Beste et
al.) by Applicant filed on Mar. 30, 2012.
[0121] The different Nanobody constructs were produced in Pichia
pastoris (see again U.S. Ser. No. 13/435,567, U.S. 61/388,172 and
U.S. 61/451,869) and afforded broadly comparable fermentation
yields (1.03 g/L for; 1.43 g/L for A007901256; 0.91 g/L for
A007901259 and 1.45 g/L for A007901260), confirming that the
present invention makes it possible to provide constructs
comprising VHH-1 type Nanobodies with expression yields that are
comparable to the expression yields of constructs that do not
contain a VHH-1 type Nanobody.
[0122] The Nanobody constructs were then purified (>99% purity
on SEC and >90% purity on RPC) and incubated at -70.degree. C.,
-20.degree. C., 5.degree. C., 25.degree. C. and 40.degree. C. at a
concentration of about 15 mg/ml in D-PBS for 7.5 weeks. The samples
were evaluated by turbidity measurement (OD500), RP-HLPC and
SE-HLPC. The results are summarized in Table 8B. Stability was
acceptable for all samples tested when stored at -70.degree. C.,
-20.degree. C. or 5.degree. C. for 7.5 weeks.
TABLE-US-00012 TABLE 8B comparative storage stability of different
anti c-Met Nanobody constructs Storage stability (7.5 weeks
incubation) Construct 25.degree. C. 40.degree. C. A007901222 0.3%
HMW; 3.5% HMW; OD500 < 0.005 OD500 = 0.005 A007901256 0.5% HMW;
24.1% HMW; OD500 < 0.005 OD500 = 1.30 (*) A007901259 0.7% HMW;
23.7% HMW; OD500 < 0.005 OD500 = 1.91 (*) A007901260 0.5% HMW;
23.1% HMW; OD500 < 0.005 OD500 = 0.45 (*) HMW = high molecular
weight (pre-peak) components (*) = sample was opalescent.
Example 6: Affinity Determination Using Surface Plasmon
Resonance
[0123] Kinetic analysis of the anti-c-Met Nanobody-Alb fusion
constructs A007900171 (SEQ ID NO:40) and A007901219 (SEQ ID NO:23)
for human, cynomolgus and mouse serum albumin was performed using
Surface Plasmon Resonance on the Biacore T100 instrument.
HBS-EP+buffer (0.01M HEPES buffer containing 0.15M NaCl, 3 mM EDTA
and 0.05% Surfactant p20, pH7.4) was used as the running buffer and
experiments were performed at 25.degree. C. Serum albumin was
chemically coupled on a Series S sensorchip chip CMS with
carboxymethylated dextran surface by a manual immobilization run at
a flow rate of 5 .mu.l/min. Surfaces were first activated with a 7
min injection of a 1:1 mixture of 75 mg/ml EDC and 11.5 mg/ml NHS
(Biacore amine coupling kit). Serum albumin was injected at 10
.mu.g/ml in 10 mM acetate pH4.5, until a level of 970 RU (flow cell
2), 890 RU (flow cell 3) and 1360 RU (flowcell 4) for respectively
human, cynomolgus and mouse serum albumin was reached. After
immobilization, surfaces were deactivated with a 7 min injection of
1M ethanolamine pH8.5. A blank reference surface (flowcell 1) was
activated and deactivated as described above. A series of Nanobody
concentrations was prepared in HBS-EP+(i.e. 0 nM, 1.9 nM, 7.8 nM,
31.25 nM, 125 nM, 500 nM, 0 nM, 7.8 nM, 125 nM), were injected for
2 min at 45 .mu.l/min (flow path 1, 2, 3, and 4) and allowed to
dissociate in running buffer for 10 min. Between different samples,
the surfaces were regenerated with regeneration buffer 10 mM
glycine-HCl pH1.5, 100 s at 45 .mu.l/min Data were double
referenced by subtraction of the curves on the reference channel
and of a blank running buffer injection curve. Processed curves
were evaluated by fitting a 1:1 binding model onto the binding
curves in the Biacore T100 Evaluation software. On-rates (ka),
off-rates (kd) and affinities (KD) were reported and are shown in
Table 9.
TABLE-US-00013 TABLE 9 Affinity determination of Nanobodies against
serum albumin by surface plasmon resonance (SPR) measurement human
serum albumin cynomolgus serum albumin mouse serum albumin ID
k.sub.on k.sub.off K.sub.D k.sub.on k.sub.off K.sub.D k.sub.on
k.sub.off K.sub.D Alb11 5.2 1.9 3.6 4.6 1.7 3.6 7.1 35 49
A007900171 (Alb11)* 1.0 6.2 60 0.93 6.1 66 0.93 66 710 Alb23 4.5
1.2 2.6 4.0 1.1 2.7 7.0 12 17 A007901219 (Alb23) 1.3 3.3 24 1.2 3.2
27 1.7 50 300 k.sub.on is given in 10.sup.5 M.sup.-1s.sup.-1,
k.sub.off is given in 10.sup.-3 s.sup.-1, K.sub.D is given in nM
(10.sup.-9 M) *Data obtained in a separate but equivalent
experiment
Example 7: Binding of the MET-Ligand HGF in Alphascreen Assay
[0124] The anti-c-MET/anti-serum albumin Nanobody constructs were
characterized in an HGF/c-MET competition AlphaScreen assay to
evaluate their blocking potency and efficacy and compare this with
a benchmark antibody fragment (5D5 Fab v2). A dilution series of
anti-c-MET Nanobodies and benchmark 5D5 Fab v2 starting from 250 nM
up to 0.9 pM was pre-incubated with 100 pM biotinylated hHGF during
15 minutes at RT. To this mixture the anti-human Fc conjugated
acceptor beads and c-MET/Fc (100 pM final concentration) were added
and incubated for 2 hours at RT. Next, streptavidin donor beads
were added and the mixture was incubated for 1 additional hour.
Fluorescence was measured by reading plates on the EnVision
Multilabel Plate Reader using an excitation wavelength of 680 nm
and an emission wavelength of 520 nm.
[0125] The two constructs effectively inhibit the HGF binding to
c-MET receptor in a dose-dependent manner. The calculated IC.sub.50
values and corresponding 95% confidence intervals are shown in
Table 10. A007900171 and the two batches of A007901219 have similar
IC50 values; their 95% CI are overlapping, which suggests that the
difference is statistically not significant. The Nanobodies showed
an >5-fold improved potency as compared to the benchmark 5D5 Fab
v2.
TABLE-US-00014 TABLE 10 Inhibition of HGF binding to cMET as
determined by Alphascreen (IC50 values and 95% confidence
intervals) ID IC.sub.50 [in pM] 95% CI [in pM] 5D5 Fab v2 380 330
to 440 A007900171 (Alb11) 58 50 to 66 A007901219 (Alb23) 66 57 to
78
Example 8: Blocking the HGF-Induced MET Phosphorylation in the A549
Cancer Cell Line
[0126] The purified anti-c-MET/anti-serum albumin Nanobody
constructs were characterized in the HGF-dependent phosphorylation
assay. A dilution series of the anti-cMET constructs or the
anti-cMET benchmark 5D5 Fab v2 starting from 1 .mu.M up to 0.23 nM
was co-incubated with 1 nM HGF on A549 cells during 15 min at
37.degree. C. 1/3 of the lysed cell solution was then applied to
the phospho c-MET MSD assay plates. Two duplicates on cell culture
level were pooled on MSD level. After washing away unbound
material, a sulfo tagged detection cMET antibody detected both the
phosphorylated as well as the unphosphorylated receptor. The read
out was performed with the sector imager 2400.
[0127] The two anti-c-MET/anti-serum albumin Nanobody constructs
effectively inhibit the HGF-dependent c-MET receptor
phosphorylation in a dose-dependent manner. The calculated
IC.sub.50 values and corresponding 95% confidence intervals are
shown in 11. A007900171 and the two batches of A007901219 have
similar IC.sub.50 values; their 95% CI are overlapping, which
suggests that the differences are statistically not significant.
The Nanobodies showed a ca. 2-fold improved potency as compared to
the benchmark 5D5 Fab v2. Additionally, within 95% confidence
intervals, the addition of human serum albumin to the stimulated
cells did not alter IC.sub.50 values of the tested Nanobodies.
TABLE-US-00015 TABLE 11 Inhibition of HGF binding to cMET as
determined by cMET phosphorylation assay (IC50 values and 95%
confidence intervals) -HSA +HSA IC.sub.50 95% CI IC.sub.50 95% CI
ID [in nM] [in nM] [in nM] [in nM] 5D5 Fab v2 11.9 8.57 to 16.5
n.d. A007900171 (Alb11) 5.97 5.08 to 7.00 6.28 5.35 to 7.36
A007901219 (Alb23) 5.41 4.61 to 6.35 4.20 3.60 to 4.91
[0128] The entire contents of all of the references (including
literature references, issued patents, published patent
applications, and co pending patent applications) cited throughout
this application are hereby expressly incorporated by reference, in
particular for the teaching that is referenced herein.
Sequence CWU 1
1
491115PRTArtificial Sequencenanobody or nanobody construct 1Glu Val
Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Ser Phe 20
25 30 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Pro Glu Trp
Val 35 40 45 Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala
Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Pro Glu
Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Ile Gly Gly Ser Leu Ser
Arg Ser Ser Gln Gly Thr Leu Val Thr 100 105 110 Val Ser Ser 115
2115PRTArtificial Sequencenanobody or nanobody construct 2Ala Val
Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asn 1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Ser Phe 20
25 30 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Glu Pro Glu Trp
Val 35 40 45 Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala
Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala
Lys Thr Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Lys Pro Glu
Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Ile Gly Gly Ser Leu Ser
Arg Ser Ser Gln Gly Thr Gln Val Thr 100 105 110 Val Ser Ser 115
3115PRTArtificial Sequencenanobody or nanobody construct 3Ala Val
Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Ser Phe 20
25 30 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Pro Glu Trp
Val 35 40 45 Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala
Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Pro Glu
Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Ile Gly Gly Ser Leu Ser
Arg Ser Ser Gln Gly Thr Leu Val Thr 100 105 110 Val Ser Ser 115
4115PRTArtificial Sequencenanobody or nanobody construct 4Ala Val
Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Ser Phe 20
25 30 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Pro Glu Trp
Val 35 40 45 Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala
Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Pro Glu
Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Ile Gly Gly Ser Leu Ser
Arg Ser Ser Gln Gly Thr Gln Val Thr 100 105 110 Val Ser Ser 115
5115PRTArtificial Sequencenanobody or nanobody construct 5Glu Val
Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Ser Phe 20
25 30 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Pro Glu Trp
Val 35 40 45 Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala
Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Pro Glu
Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Ile Gly Gly Ser Leu Ser
Arg Ser Ser Gln Gly Thr Gln Val Thr 100 105 110 Val Ser Ser 115
6116PRTArtificial Sequencenanobody or nanobody construct 6Glu Val
Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Ser Phe 20
25 30 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Pro Glu Trp
Val 35 40 45 Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala
Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Pro Glu
Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Ile Gly Gly Ser Leu Ser
Arg Ser Ser Gln Gly Thr Leu Val Thr 100 105 110 Val Ser Ser Ala 115
7117PRTArtificial Sequencenanobody or nanobody construct 7Glu Val
Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Ser Phe 20
25 30 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Pro Glu Trp
Val 35 40 45 Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala
Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Pro Glu
Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Ile Gly Gly Ser Leu Ser
Arg Ser Ser Gln Gly Thr Leu Val Thr 100 105 110 Val Ser Ser Ala Ala
115 8118PRTArtificial Sequencenanobody or nanobody construct 8Glu
Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10
15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Ser Phe
20 25 30 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Pro Glu
Trp Val 35 40 45 Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr
Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn
Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Pro
Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Ile Gly Gly Ser Leu
Ser Arg Ser Ser Gln Gly Thr Leu Val Thr 100 105 110 Val Ser Ser Ala
Ala Ala 115 9116PRTArtificial Sequencenanobody or nanobody
construct 9Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro
Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr
Phe Arg Ser Phe 20 25 30 Gly Met Ser Trp Val Arg Gln Ala Pro Gly
Lys Gly Pro Glu Trp Val 35 40 45 Ser Ser Ile Ser Gly Ser Gly Ser
Asp Thr Leu Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile
Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn
Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Ile
Gly Gly Ser Leu Ser Arg Ser Ser Gln Gly Thr Leu Val Thr 100 105 110
Val Ser Ser Gly 115 10117PRTArtificial Sequencenanobody or nanobody
construct 10Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro
Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr
Phe Arg Ser Phe 20 25 30 Gly Met Ser Trp Val Arg Gln Ala Pro Gly
Lys Gly Pro Glu Trp Val 35 40 45 Ser Ser Ile Ser Gly Ser Gly Ser
Asp Thr Leu Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile
Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn
Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Ile
Gly Gly Ser Leu Ser Arg Ser Ser Gln Gly Thr Leu Val Thr 100 105 110
Val Ser Ser Gly Gly 115 11118PRTArtificial Sequencenanobody or
nanobody construct 11Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu
Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser
Gly Phe Thr Phe Arg Ser Phe 20 25 30 Gly Met Ser Trp Val Arg Gln
Ala Pro Gly Lys Gly Pro Glu Trp Val 35 40 45 Ser Ser Ile Ser Gly
Ser Gly Ser Asp Thr Leu Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg
Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu
Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90
95 Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser Gln Gly Thr Leu Val Thr
100 105 110 Val Ser Ser Gly Gly Gly 115 12125PRTArtificial
Sequencenanobody or nanobody construct 12Glu Val Gln Leu Val Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Ile Leu Asp Tyr Tyr 20 25 30 Ala Ile
Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val 35 40 45
Leu Cys Ile Asp Ala Ser Asp Asp Ile Thr Tyr Tyr Ala Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val
Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Gly Val
Tyr Tyr Cys 85 90 95 Ala Thr Pro Ile Gly Leu Ser Ser Ser Cys Leu
Leu Glu Tyr Asp Tyr 100 105 110 Asp Tyr Trp Gly Gln Gly Thr Leu Val
Thr Val Ser Ser 115 120 125 13125PRTArtificial Sequencenanobody or
nanobody construct 13Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu
Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser
Gly Phe Ile Leu Asp Tyr Tyr 20 25 30 Ala Ile Gly Trp Phe Arg Gln
Ala Pro Gly Lys Glu Arg Glu Gly Val 35 40 45 Ser Cys Ile Asp Ala
Ser Asp Asp Ile Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg
Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr 65 70 75 80 Leu
Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Gly Val Tyr Tyr Cys 85 90
95 Ala Thr Pro Ile Gly Leu Ser Ser Ser Cys Leu Leu Glu Tyr Asp Tyr
100 105 110 Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115
120 125 14125PRTArtificial Sequencenanobody or nanobody construct
14Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1
5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Leu Asp Tyr
Tyr 20 25 30 Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg
Glu Gly Val 35 40 45 Leu Ser Ile Asp Ala Ser Asp Asp Ile Thr Tyr
Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp
Asn Ala Lys Asn Thr Val Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Lys
Pro Glu Asp Thr Gly Val Tyr Tyr Cys 85 90 95 Ala Thr Pro Ile Gly
Leu Ser Ser Ser Gly Leu Leu Glu Tyr Asp Tyr 100 105 110 Asp Tyr Trp
Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125
15125PRTArtificial Sequencenanobody or nanobody construct 15Glu Val
Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15
Ser Leu Arg Leu Ser Ala Ala Ala Ser Gly Phe Ile Leu Asp Tyr Tyr 20
25 30 Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly
Val 35 40 45 Leu Cys Ile Asp Ala Ser Asp Asp Ile Thr Tyr Tyr Ala
Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala
Lys Asn Thr Val Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Lys Pro Glu
Asp Thr Gly Val Tyr Tyr Ser 85 90 95 Ala Thr Pro Ile Gly Leu Ser
Ser Ser Cys Leu Leu Glu Tyr Asp Tyr 100 105 110 Asp Tyr Trp Gly Gln
Gly Thr Leu Val Thr Val Ser Ser 115 120 125 16125PRTArtificial
Sequencenanobody or nanobody construct 16Glu Val Gln Leu Val Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Ile Leu Asp Tyr Tyr 20 25 30 Ala Ile
Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val 35 40 45
Leu Cys Ile Asp Ala Ser Asp Asp Ile Thr Tyr Tyr Ala Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val
Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Gly Val
Tyr Tyr Cys 85 90 95 Ala Thr Pro Ile Gly Leu Ser Ser Ser Cys Leu
Leu Glu Tyr Asp Tyr 100 105 110 Asp Tyr Trp Gly Gln Gly Thr Leu Val
Thr Val Ser Ser 115 120 125 17125PRTArtificial Sequencenanobody or
nanobody construct 17Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu
Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser
Gly Phe Ile Leu Asp Tyr Tyr 20 25 30 Ala Ile Gly Trp Phe Arg Gln
Ala Pro Gly Lys Glu Arg Glu Gly Val 35 40 45 Leu Cys Ile Asp Ala
Ser Asp Asp Ile Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg
Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr 65 70 75 80 Leu
Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Gly Val Tyr Tyr Cys 85 90
95 Ala Thr Pro Ile Gly Leu Ser Ser Ser Cys Leu Leu Glu Tyr Asp Tyr
100 105 110 Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115
120 125 18125PRTArtificial Sequencenanobody or nanobody construct
18Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1
5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Leu Asp Tyr
Tyr 20 25 30 Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg
Glu Gly Val 35 40 45 Leu Cys Ile Asp Ala Ser Asp Asp Ile Thr Tyr
Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp
Asn Ser Lys Asn Thr Val Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg
Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Thr Pro Ile Gly
Leu Ser Ser Ser Cys Leu Leu Glu Tyr Asp Tyr 100 105 110 Asp Tyr Trp
Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125
19125PRTArtificial Sequencenanobody or nanobody construct 19Asp Val
Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Leu Asp Tyr Tyr 20
25 30 Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly
Val 35 40 45 Leu Cys Ile Asp Ala Ser Asp Asp Ile Thr Tyr Tyr Ala
Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
Lys Asn Thr Val Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Pro Glu
Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Thr Pro Ile Gly Leu Ser
Ser Ser Cys Leu Leu Glu Tyr Asp Tyr 100 105 110 Asp Tyr Trp Gly Gln
Gly Thr Leu Val Thr Val Ser Ser 115 120 125 20249PRTArtificial
Sequencenanobody or nanobody construct 20Glu Val Gln Leu Leu Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Ser Phe 20 25 30 Gly Met
Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Pro Glu Trp Val 35 40 45
Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu
Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val
Tyr Tyr Cys 85 90 95 Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser Gln
Gly Thr Leu Val Thr 100 105 110 Val Ser Ser Gly Gly Gly Gly Ser Gly
Gly Gly Ser Glu Val Gln Leu 115 120 125 Val Glu Ser Gly Gly Gly Leu
Val Gln Pro Gly Gly Ser Leu Arg Leu 130 135 140 Ser Cys Ala Ala Ser
Gly Phe Ile Leu Asp Tyr Tyr Ala Ile Gly Trp 145 150 155 160 Phe Arg
Gln Ala Pro Gly Lys Glu Arg Glu Gly Val Leu Cys Ile Asp 165 170 175
Ala Ser Asp Asp Ile Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe 180
185 190 Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met
Asn 195 200 205 Ser Leu Lys Pro Glu Asp Thr Gly Val Tyr Tyr Cys Ala
Thr Pro Ile 210 215 220 Gly Leu Ser Ser Ser Cys Leu Leu Glu Tyr Asp
Tyr Asp Tyr Trp Gly 225 230 235 240 Gln Gly Thr Leu Val Thr Val Ser
Ser 245 21249PRTArtificial Sequencenanobody or nanobody construct
21Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1
5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Leu Asp Tyr
Tyr 20 25 30 Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg
Glu Gly Val 35 40 45 Leu Cys Ile Asp Ala Ser Asp Asp Ile Thr Tyr
Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp
Asn Ala Lys Asn Thr Val Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Lys
Pro Glu Asp Thr Gly Val Tyr Tyr Cys 85 90 95 Ala Thr Pro Ile Gly
Leu Ser Ser Ser Cys Leu Leu Glu Tyr Asp Tyr 100 105 110 Asp Tyr Trp
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125 Gly
Ser Gly Gly Gly Ser Glu Val Gln Leu Leu Glu Ser Gly Gly Gly 130 135
140 Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly
145 150 155 160 Phe Thr Phe Arg Ser Phe Gly Met Ser Trp Val Arg Gln
Ala Pro Gly 165 170 175 Lys Gly Pro Glu Trp Val Ser Ser Ile Ser Gly
Ser Gly Ser Asp Thr 180 185 190 Leu Tyr Ala Asp Ser Val Lys Gly Arg
Phe Thr Ile Ser Arg Asp Asn 195 200 205 Ser Lys Asn Thr Leu Tyr Leu
Gln Met Asn Ser Leu Arg Pro Glu Asp 210 215 220 Thr Ala Val Tyr Tyr
Cys Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser 225 230 235 240 Gln Gly
Thr Leu Val Thr Val Ser Ser 245 22249PRTArtificial Sequencenanobody
or nanobody construct 22Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu
Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser
Gly Phe Thr Phe Arg Ser Phe 20 25 30 Gly Met Ser Trp Val Arg Gln
Ala Pro Gly Lys Gly Pro Glu Trp Val 35 40 45 Ser Ser Ile Ser Gly
Ser Gly Ser Asp Thr Leu Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg
Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu
Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90
95 Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser Gln Gly Thr Leu Val Thr
100 105 110 Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser Asp Val
Gln Leu 115 120 125 Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
Ser Leu Arg Leu 130 135 140 Ser Cys Ala Ala Ser Gly Phe Ile Leu Asp
Tyr Tyr Ala Ile Gly Trp 145 150 155 160 Phe Arg Gln Ala Pro Gly Lys
Glu Arg Glu Gly Val Leu Cys Ile Asp 165 170 175 Ala Ser Asp Asp Ile
Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe 180 185 190 Thr Ile Ser
Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu Gln Met Asn 195 200 205 Ser
Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Thr Pro Ile 210 215
220 Gly Leu Ser Ser Ser Cys Leu Leu Glu Tyr Asp Tyr Asp Tyr Trp Gly
225 230 235 240 Gln Gly Thr Leu Val Thr Val Ser Ser 245
23249PRTArtificial Sequencenanobody or nanobody construct 23Asp Val
Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Leu Asp Tyr Tyr 20
25 30 Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly
Val 35 40 45 Leu Cys Ile Asp Ala Ser Asp Asp Ile Thr Tyr Tyr Ala
Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
Lys Asn Thr Val Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Pro Glu
Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Thr Pro Ile Gly Leu Ser
Ser Ser Cys Leu Leu Glu Tyr Asp Tyr 100 105 110 Asp Tyr Trp Gly Gln
Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125 Gly Ser Gly
Gly Gly Ser Glu Val Gln Leu Leu Glu Ser Gly Gly Gly 130 135 140 Leu
Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly 145 150
155 160 Phe Thr Phe Arg Ser Phe Gly Met Ser Trp Val Arg Gln Ala Pro
Gly 165 170 175 Lys Gly Pro Glu Trp Val Ser Ser Ile Ser Gly Ser Gly
Ser Asp Thr 180 185 190 Leu Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr
Ile Ser Arg Asp Asn 195 200 205 Ser Lys Asn Thr Leu Tyr Leu Gln Met
Asn Ser Leu Arg Pro Glu Asp 210 215 220 Thr Ala Val Tyr Tyr Cys Thr
Ile Gly Gly Ser Leu Ser Arg Ser Ser 225 230 235 240 Gln Gly Thr Leu
Val Thr Val Ser Ser 245 24275PRTArtificial Sequencenanobody or
nanobody construct 24Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu
Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser
Gly Phe Thr Phe Arg Ser Phe 20 25 30 Gly Met Ser Trp Val Arg Gln
Ala Pro Gly Lys Gly Pro Glu Trp Val 35 40 45 Ser Ser Ile Ser Gly
Ser Gly Ser Asp Thr Leu Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg
Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu
Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90
95 Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser Gln Gly Thr Leu Val Thr
100 105 110 Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
Gly Gly 115 120 125 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly 130 135 140 Ser Gly Gly Gly Gly Ser Glu Val Gln Leu
Val Glu Ser Gly Gly Gly 145 150 155 160 Leu Val Gln Pro Gly Gly Ser
Leu Arg Leu Ser Cys Ala Ala Ser Gly 165 170 175 Phe Ile Leu Asp Tyr
Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly 180 185 190 Lys Glu Arg
Glu Gly Val Leu Cys Ile Asp Ala Ser Asp Asp Ile Thr 195 200 205 Tyr
Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn 210 215
220 Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp
225 230 235 240 Thr Gly Val Tyr Tyr Cys Ala Thr Pro Ile Gly Leu Ser
Ser Ser Cys 245 250 255 Leu Leu Glu Tyr Asp Tyr Asp Tyr Trp Gly Gln
Gly Thr Leu Val Thr 260 265 270 Val Ser Ser 275 25275PRTArtificial
Sequencenanobody or nanobody construct 25Glu Val Gln Leu Val Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Ile Leu Asp Tyr Tyr 20 25 30 Ala Ile
Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val 35 40 45
Leu Cys Ile Asp Ala Ser Asp Asp Ile Thr Tyr Tyr Ala Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val
Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Gly Val
Tyr Tyr Cys 85 90 95 Ala Thr Pro Ile Gly Leu Ser Ser Ser Cys Leu
Leu Glu Tyr Asp Tyr 100 105 110 Asp Tyr Trp Gly Gln Gly Thr Leu Val
Thr Val Ser Ser Gly Gly Gly 115 120 125 Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly 130 135 140 Ser Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 145 150 155 160 Glu Val
Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 165 170 175
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Ser Phe 180
185 190 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Pro Glu Trp
Val 195 200 205 Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala
Asp Ser Val 210 215 220 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
Lys Asn Thr Leu Tyr 225 230 235 240 Leu Gln Met Asn Ser Leu Arg Pro
Glu Asp Thr Ala Val Tyr Tyr Cys 245 250 255 Thr Ile Gly Gly Ser Leu
Ser Arg Ser Ser Gln Gly Thr Leu Val Thr 260 265 270 Val Ser Ser 275
26275PRTArtificial Sequencenanobody or nanobody construct 26Glu Val
Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Ser Phe 20
25 30 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Pro Glu Trp
Val 35 40 45 Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala
Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Pro Glu
Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Ile Gly Gly Ser Leu Ser
Arg Ser Ser Gln Gly Thr Leu Val Thr 100 105 110 Val Ser Ser Gly Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 115 120 125 Gly Ser Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 130 135 140 Ser
Gly Gly Gly Gly Ser Asp Val Gln Leu Val Glu Ser Gly Gly Gly 145 150
155 160 Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser
Gly 165 170 175 Phe Ile Leu Asp Tyr Tyr Ala Ile Gly Trp Phe Arg Gln
Ala Pro Gly 180 185 190 Lys Glu Arg Glu Gly Val Leu Cys Ile Asp Ala
Ser Asp Asp Ile Thr 195 200 205 Tyr Tyr Ala Asp Ser Val Lys Gly Arg
Phe Thr Ile Ser Arg Asp Asn 210 215 220 Ser Lys Asn Thr Val Tyr Leu
Gln Met Asn Ser Leu Arg Pro Glu Asp 225 230 235 240 Thr Ala Val Tyr
Tyr Cys Ala Thr Pro Ile Gly Leu Ser Ser Ser Cys 245 250 255 Leu Leu
Glu Tyr Asp Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr 260 265 270
Val Ser Ser 275 27275PRTArtificial Sequencenanobody or nanobody
construct 27Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro
Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile
Leu Asp Tyr Tyr 20 25 30 Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly
Lys Glu Arg Glu Gly Val 35 40 45 Leu Cys Ile Asp Ala Ser Asp Asp
Ile Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile
Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr 65 70 75 80 Leu Gln Met Asn
Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Thr
Pro Ile Gly Leu Ser Ser Ser Cys Leu Leu Glu Tyr Asp Tyr 100 105 110
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115
120 125 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly 130 135 140 Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly Ser 145 150 155 160 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly
Leu Val Gln Pro Gly Gly 165 170 175 Ser Leu Arg Leu Ser Cys Ala Ala
Ser Gly Phe Thr Phe Arg Ser Phe 180 185 190 Gly Met Ser Trp Val Arg
Gln Ala Pro Gly Lys Gly Pro Glu Trp Val 195 200 205 Ser Ser Ile Ser
Gly Ser Gly Ser Asp Thr Leu Tyr Ala Asp Ser Val 210 215 220 Lys Gly
Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 225 230 235
240 Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys
245 250 255 Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser Gln Gly Thr Leu
Val Thr 260 265 270 Val Ser Ser 275 28383PRTArtificial
Sequencenanobody or nanobody construct 28Asp Val Gln
Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser
Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Leu Asp Tyr Tyr 20 25
30 Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val
35 40 45 Leu Cys Ile Asp Ala Ser Asp Asp Ile Thr Tyr Tyr Ala Asp
Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys
Asn Thr Val Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Pro Glu Asp
Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Thr Pro Ile Gly Leu Ser Ser
Ser Cys Leu Leu Glu Tyr Asp Tyr 100 105 110 Asp Tyr Trp Gly Gln Gly
Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125 Gly Ser Gly Gly
Gly Ser Asp Val Gln Leu Val Glu Ser Gly Gly Gly 130 135 140 Leu Val
Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly 145 150 155
160 Phe Ile Leu Asp Tyr Tyr Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly
165 170 175 Lys Glu Arg Glu Gly Val Leu Cys Ile Asp Ala Ser Asp Asp
Ile Thr 180 185 190 Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile
Ser Arg Asp Asn 195 200 205 Ser Lys Asn Thr Val Tyr Leu Gln Met Asn
Ser Leu Arg Pro Glu Asp 210 215 220 Thr Ala Val Tyr Tyr Cys Ala Thr
Pro Ile Gly Leu Ser Ser Ser Cys 225 230 235 240 Leu Leu Glu Tyr Asp
Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr 245 250 255 Val Ser Ser
Gly Gly Gly Gly Ser Gly Gly Gly Ser Glu Val Gln Leu 260 265 270 Leu
Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu 275 280
285 Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Ser Phe Gly Met Ser Trp
290 295 300 Val Arg Gln Ala Pro Gly Lys Gly Pro Glu Trp Val Ser Ser
Ile Ser 305 310 315 320 Gly Ser Gly Ser Asp Thr Leu Tyr Ala Asp Ser
Val Lys Gly Arg Phe 325 330 335 Thr Ile Ser Arg Asp Asn Ser Lys Asn
Thr Leu Tyr Leu Gln Met Asn 340 345 350 Ser Leu Arg Pro Glu Asp Thr
Ala Val Tyr Tyr Cys Thr Ile Gly Gly 355 360 365 Ser Leu Ser Arg Ser
Ser Gln Gly Thr Leu Val Thr Val Ser Ser 370 375 380
295PRTArtificial Sequencenanobody or nanobody construct 29Ser Phe
Gly Met Ser 1 5 3017PRTArtificial Sequencenanobody or nanobody
construct 30Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala Asp Ser
Val Lys 1 5 10 15 Gly 316PRTArtificial Sequencenanobody or nanobody
construct 31Gly Gly Ser Leu Ser Arg 1 5 32115PRTArtificial
Sequencenanobody or nanobody construct 32Glu Val Gln Leu Val Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 20 25 30 Gly Met
Ser Trp Val Arg Gln Ala Pro Gly Lys Glu Pro Glu Trp Val 35 40 45
Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Thr Thr Leu
Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val
Tyr Tyr Cys 85 90 95 Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser Gln
Gly Thr Gln Val Thr 100 105 110 Val Ser Ser 115 33115PRTArtificial
Sequencenanobody or nanobody construct 33Glu Val Gln Leu Val Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Ser Phe 20 25 30 Gly Met
Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45
Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Thr Thr Leu
Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val
Tyr Tyr Cys 85 90 95 Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser Gln
Gly Thr Gln Val Thr 100 105 110 Val Ser Ser 115 34115PRTArtificial
Sequencenanobody or nanobody construct 34Glu Val Gln Leu Val Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Asn 1 5 10 15 Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Ser Phe 20 25 30 Gly Met
Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45
Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Thr Thr Leu
Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val
Tyr Tyr Cys 85 90 95 Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser Gln
Gly Thr Leu Val Thr 100 105 110 Val Ser Ser 115 35115PRTArtificial
Sequencenanobody or nanobody construct 35Glu Val Gln Leu Val Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Asn 1 5 10 15 Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Ser Phe 20 25 30 Gly Met
Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45
Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Thr Thr Leu
Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val
Tyr Tyr Cys 85 90 95 Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser Gln
Gly Thr Leu Val Thr 100 105 110 Val Ser Ser 115 36115PRTArtificial
Sequencenanobody or nanobody construct 36Glu Val Gln Leu Val Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Asn 1 5 10 15 Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 20 25 30 Gly Met
Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45
Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Thr Thr Leu
Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val
Tyr Tyr Cys 85 90 95 Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser Gln
Gly Thr Leu Val Thr 100 105 110 Val Ser Ser 115 37115PRTArtificial
Sequencenanobody or nanobody construct 37Glu Val Gln Leu Val Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Asn 1 5 10 15 Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 20 25 30 Gly Met
Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45
Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu
Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val
Tyr Tyr Cys 85 90 95 Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser Gln
Gly Thr Leu Val Thr 100 105 110 Val Ser Ser 115 38115PRTArtificial
Sequencenanobody or nanobody construct 38Glu Val Gln Leu Val Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Asn 1 5 10 15 Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 20 25 30 Gly Met
Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45
Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu Tyr Ala Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu
Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val
Tyr Tyr Cys 85 90 95 Thr Ile Gly Gly Ser Leu Ser Arg Ser Gly Gln
Gly Thr Leu Val Thr 100 105 110 Val Ser Ser 115 39283PRTArtificial
Sequencenanobody or nanobody construct 39Glu Val Gln Leu Val Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Ile Leu Asp Tyr Tyr 20 25 30 Ala Ile
Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val 35 40 45
Leu Cys Ile Asp Ala Ser Asp Asp Ile Thr Tyr Tyr Ala Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val
Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Gly Val
Tyr Tyr Cys 85 90 95 Ala Thr Pro Ile Gly Leu Ser Ser Ser Cys Leu
Leu Glu Tyr Asp Tyr 100 105 110 Asp Tyr Trp Gly Gln Gly Thr Leu Val
Thr Val Ser Ser Gly Gly Gly 115 120 125 Gly Ser Gly Gly Gly Ser Glu
Val Gln Leu Val Glu Ser Gly Gly Gly 130 135 140 Leu Val Gln Pro Gly
Asn Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly 145 150 155 160 Phe Thr
Phe Ser Ser Phe Gly Met Ser Trp Val Arg Gln Ala Pro Gly 165 170 175
Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr 180
185 190 Leu Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp
Asn 195 200 205 Ala Lys Thr Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg
Pro Glu Asp 210 215 220 Thr Ala Val Tyr Tyr Cys Thr Ile Gly Gly Ser
Leu Ser Arg Ser Ser 225 230 235 240 Gln Gly Thr Leu Val Thr Val Ser
Ser Gly Ala Ala Asp Tyr Lys Asp 245 250 255 His Asp Gly Asp Tyr Lys
Asp His Asp Ile Asp Tyr Lys Asp Asp Asp 260 265 270 Asp Lys Gly Ala
Ala His His His His His His 275 280 40249PRTArtificial
Sequencenanobody or nanobody construct 40Asp Val Gln Leu Val Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Ile Leu Asp Tyr Tyr 20 25 30 Ala Ile
Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Gly Val 35 40 45
Leu Cys Ile Asp Ala Ser Asp Asp Ile Thr Tyr Tyr Ala Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val
Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val
Tyr Tyr Cys 85 90 95 Ala Thr Pro Ile Gly Leu Ser Ser Ser Cys Leu
Leu Glu Tyr Asp Tyr 100 105 110 Asp Tyr Trp Gly Gln Gly Thr Leu Val
Thr Val Ser Ser Gly Gly Gly 115 120 125 Gly Ser Gly Gly Gly Ser Glu
Val Gln Leu Val Glu Ser Gly Gly Gly 130 135 140 Leu Val Gln Pro Gly
Asn Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly 145 150 155 160 Phe Thr
Phe Ser Ser Phe Gly Met Ser Trp Val Arg Gln Ala Pro Gly 165 170 175
Lys Gly Leu Glu Trp Val Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr 180
185 190 Leu Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp
Asn 195 200 205 Ala Lys Thr Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg
Pro Glu Asp 210 215 220 Thr Ala Val Tyr Tyr Cys Thr Ile Gly Gly Ser
Leu Ser Arg Ser Ser 225 230 235 240 Gln Gly Thr Leu Val Thr Val Ser
Ser 245 41246PRTArtificial Sequencenanobody or nanobody construct
41Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1
5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Asn
Tyr 20 25 30 Asp Met Ala Trp Val Arg Gln Ala Pro Gly Lys Arg Pro
Glu Trp Val 35 40 45 Ser Ser Ile Asp Thr Gly Gly Asp Ile Thr His
Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp
Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg
Pro Glu Asp Thr Ala Val Tyr Trp Cys 85 90 95 Ala Thr Asp Glu Glu
Tyr Ala Leu Gly Pro Asn Glu Phe Asp Tyr Tyr 100 105 110 Gly Gln Gly
Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly 115 120 125 Gly
Gly Ser Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln 130 135
140 Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
145 150 155 160 Arg Ser Phe Gly Met Ser Trp Val Arg Gln Ala Pro Gly
Lys Gly Pro 165 170 175 Glu Trp Val Ser Ser Ile Ser Gly Ser Gly Ser
Asp Thr Leu Tyr Ala 180 185 190 Asp Ser Val Lys Gly Arg Phe Thr Ile
Ser Arg Asp Asn Ser Lys Asn 195 200 205 Thr Leu Tyr Leu Gln Met Asn
Ser Leu Arg Pro Glu Asp Thr Ala Val 210 215 220 Tyr Tyr Cys Thr Ile
Gly Gly Ser Leu Ser Arg Ser Ser Gln Gly Thr 225 230 235 240 Leu Val
Thr Val Ser Ser 245 42246PRTArtificial Sequencenanobody or nanobody
construct 42Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro
Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr
Phe Gly Asn Tyr 20 25 30 Asp Met Ala Trp Val Arg Gln Ala Pro Gly
Lys Arg Pro Glu Trp Val 35 40 45 Ser Ser Ile Asp Thr Gly Gly Asp
Ile Thr His Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile
Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn
Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Trp Cys 85 90 95 Ala Thr
Asp Glu Glu Tyr Ala Leu Gly Pro Asn Glu Phe Asp Tyr Tyr 100 105 110
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly 115
120 125 Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val
Gln 130 135 140 Pro Gly Asn Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly
Phe Thr Phe 145 150 155 160 Ser Ser Phe Gly Met Ser Trp Val Arg Gln
Ala Pro Gly Lys Gly Leu 165 170 175 Glu Trp Val Ser Ser Ile Ser Gly
Ser Gly Ser Asp Thr Leu Tyr Ala 180 185 190 Asp Ser Val Lys Gly Arg
Phe Thr Ile
Ser Arg Asp Asn Ala Lys Thr 195 200 205 Thr Leu Tyr Leu Gln Met Asn
Ser Leu Arg Pro Glu Asp Thr Ala Val 210 215 220 Tyr Tyr Cys Thr Ile
Gly Gly Ser Leu Ser Arg Ser Ser Gln Gly Thr 225 230 235 240 Leu Val
Thr Val Ser Ser 245 43122PRTArtificial Sequencenanobody or nanobody
construct 43Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro
Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr
Phe Gly Asn Tyr 20 25 30 Asp Met Ala Trp Val Arg Gln Ala Pro Gly
Lys Arg Pro Glu Trp Val 35 40 45 Ser Ser Ile Asp Thr Gly Gly Asp
Ile Thr His Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile
Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn
Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Trp Cys 85 90 95 Ala Thr
Asp Glu Glu Tyr Ala Leu Gly Pro Asn Glu Phe Asp Tyr Tyr 100 105 110
Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 44433PRTArtificial
Sequencenanobody or nanobody construct 44Asp Val Gln Leu Val Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Ile 20 25 30 Tyr Ala
Lys Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe 35 40 45
Val Ala Ala Ile Ser Arg Ser Gly Arg Ser Thr Ser Tyr Ala Asp Ser 50
55 60 Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr
Val 65 70 75 80 Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala
Val Tyr Tyr 85 90 95 Cys Ala Ala Val Gly Gly Ala Thr Thr Val Thr
Ala Ser Glu Trp Asp 100 105 110 Tyr Trp Gly Gln Gly Thr Leu Val Thr
Val Ser Ser Gly Gly Gly Gly 115 120 125 Ser Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser 130 135 140 Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu 145 150 155 160 Val Gln
Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser 165 170 175
Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Ser Ile Tyr 180
185 190 Ala Lys Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe
Val 195 200 205 Ala Ala Ile Ser Arg Ser Gly Arg Ser Thr Ser Tyr Ala
Asp Ser Val 210 215 220 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser
Lys Asn Thr Val Tyr 225 230 235 240 Leu Gln Met Asn Ser Leu Arg Pro
Glu Asp Thr Ala Val Tyr Tyr Cys 245 250 255 Ala Ala Val Gly Gly Ala
Thr Thr Val Thr Ala Ser Glu Trp Asp Tyr 260 265 270 Trp Gly Gln Gly
Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser 275 280 285 Gly Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 290 295 300
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Val 305
310 315 320 Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Asn
Ser Leu 325 330 335 Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser
Ser Phe Gly Met 340 345 350 Ser Trp Val Arg Gln Ala Pro Gly Lys Gly
Leu Glu Trp Val Ser Ser 355 360 365 Ile Ser Gly Ser Gly Ser Asp Thr
Leu Tyr Ala Asp Ser Val Lys Gly 370 375 380 Arg Phe Thr Ile Ser Arg
Asp Asn Ala Lys Thr Thr Leu Tyr Leu Gln 385 390 395 400 Met Asn Ser
Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys Thr Ile 405 410 415 Gly
Gly Ser Leu Ser Arg Ser Ser Gln Gly Thr Leu Val Thr Val Ser 420 425
430 Ser 45250PRTArtificial Sequencenanobody or nanobody construct
45Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1
5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ile Leu Asp Tyr
Tyr 20 25 30 Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg
Glu Gly Val 35 40 45 Leu Cys Ile Asp Ala Ser Asp Asp Ile Thr Tyr
Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp
Asn Ser Lys Asn Thr Val Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg
Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Thr Pro Ile Gly
Leu Ser Ser Ser Cys Leu Leu Glu Tyr Asp Tyr 100 105 110 Asp Tyr Trp
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly 115 120 125 Gly
Ser Gly Gly Gly Ser Glu Val Gln Leu Leu Glu Ser Gly Gly Gly 130 135
140 Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly
145 150 155 160 Phe Thr Phe Arg Ser Phe Gly Met Ser Trp Val Arg Gln
Ala Pro Gly 165 170 175 Lys Gly Pro Glu Trp Val Ser Ser Ile Ser Gly
Ser Gly Ser Asp Thr 180 185 190 Leu Tyr Ala Asp Ser Val Lys Gly Arg
Phe Thr Ile Ser Arg Asp Asn 195 200 205 Ser Lys Asn Thr Leu Tyr Leu
Gln Met Asn Ser Leu Arg Pro Glu Asp 210 215 220 Thr Ala Val Tyr Tyr
Cys Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser 225 230 235 240 Gln Gly
Thr Leu Val Thr Val Ser Ser Ala 245 250 46249PRTArtificial
Sequencenanobody or nanobody construct 46Asp Val Gln Leu Val Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Ala Phe Asp Asp Tyr 20 25 30 Ala Ile
Gly Trp Phe Arg Gln Ala Pro Gly Glu Glu Arg Glu Gly Val 35 40 45
Ser Ser Ile Ser Ser Thr Tyr Gly Leu Thr Tyr Tyr Ala Asp Ser Val 50
55 60 Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn Ser Lys Asn Thr Val
Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val
Tyr Tyr Cys 85 90 95 Ala Ala Thr Pro Ile Gly Leu Ile Gly Leu Asp
Ala Tyr Glu Tyr Asp 100 105 110 Tyr Trp Gly Gln Gly Thr Leu Val Thr
Val Ser Ser Gly Gly Gly Gly 115 120 125 Ser Gly Gly Gly Ser Glu Val
Gln Leu Val Glu Ser Gly Gly Gly Leu 130 135 140 Val Gln Pro Gly Asn
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe 145 150 155 160 Thr Phe
Ser Ser Phe Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys 165 170 175
Gly Leu Glu Trp Val Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu 180
185 190 Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn
Ala 195 200 205 Lys Thr Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Pro
Glu Asp Thr 210 215 220 Ala Val Tyr Tyr Cys Thr Ile Gly Gly Ser Leu
Ser Arg Ser Ser Gln 225 230 235 240 Gly Thr Leu Val Thr Val Ser Ser
Ala 245 47249PRTArtificial Sequencenanobody or nanobody construct
47Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1
5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp
Tyr 20 25 30 Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Glu Glu Arg
Leu Gly Val 35 40 45 Ser Ser Ile Ser Ser Thr Tyr Gly Leu Thr Tyr
Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Ser Asp
Asn Ser Lys Asn Thr Val Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg
Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ala Thr Pro Ile
Gly Leu Ile Gly Leu Asp Ala Tyr Glu Tyr Asp 100 105 110 Tyr Trp Gly
Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly 115 120 125 Ser
Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu 130 135
140 Val Gln Pro Gly Asn Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
145 150 155 160 Thr Phe Ser Ser Phe Gly Met Ser Trp Val Arg Gln Ala
Pro Gly Lys 165 170 175 Gly Leu Glu Trp Val Ser Ser Ile Ser Gly Ser
Gly Ser Asp Thr Leu 180 185 190 Tyr Ala Asp Ser Val Lys Gly Arg Phe
Thr Ile Ser Arg Asp Asn Ala 195 200 205 Lys Thr Thr Leu Tyr Leu Gln
Met Asn Ser Leu Arg Pro Glu Asp Thr 210 215 220 Ala Val Tyr Tyr Cys
Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser Gln 225 230 235 240 Gly Thr
Leu Val Thr Val Ser Ser Ala 245 48249PRTArtificial Sequencenanobody
or nanobody construct 48Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu
Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser
Gly Phe Thr Phe Asp Asp Tyr 20 25 30 Ala Ile Gly Trp Phe Arg Gln
Ala Pro Gly Glu Glu Arg Leu Gly Val 35 40 45 Ser Ser Ile Ser Ser
Thr Tyr Gly Leu Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg
Phe Thr Ile Ser Ser Asp Asn Ser Lys Asn Thr Val Tyr 65 70 75 80 Leu
Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90
95 Ala Ala Thr Pro Ile Gly Leu Ile Gly Leu Asp Ala Tyr Glu Tyr Asp
100 105 110 Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly
Gly Gly 115 120 125 Ser Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser
Gly Gly Gly Leu 130 135 140 Val Gln Pro Gly Asn Ser Leu Arg Leu Ser
Cys Ala Ala Ser Gly Phe 145 150 155 160 Thr Phe Ser Ser Phe Gly Met
Ser Trp Val Arg Gln Ala Pro Gly Lys 165 170 175 Gly Leu Glu Trp Val
Ser Ser Ile Ser Gly Ser Gly Ser Asp Thr Leu 180 185 190 Tyr Ala Asp
Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala 195 200 205 Lys
Thr Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr 210 215
220 Ala Val Tyr Tyr Cys Thr Ile Gly Gly Ser Leu Ser Arg Ser Ser Gln
225 230 235 240 Gly Thr Leu Val Thr Val Ser Ser Ala 245
49249PRTArtificial Sequencenanobody or nanobody construct 49Asp Val
Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Asp Asp Tyr 20
25 30 Ala Ile Gly Trp Phe Arg Gln Ala Pro Gly Glu Glu Arg Leu Gly
Val 35 40 45 Ser Ser Ile Ser Ser Thr Tyr Gly Leu Thr Tyr Tyr Ala
Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Ser Asp Asn Ser
Lys Asn Thr Val Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Pro Glu
Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ala Thr Pro Ile Gly Leu
Ile Gly Leu Asp Ala Tyr Glu Tyr Asp 100 105 110 Tyr Trp Gly Gln Gly
Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly 115 120 125 Ser Gly Gly
Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu 130 135 140 Val
Gln Pro Gly Asn Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe 145 150
155 160 Thr Phe Ser Ser Phe Gly Met Ser Trp Val Arg Gln Ala Pro Gly
Lys 165 170 175 Gly Leu Glu Trp Val Ser Ser Ile Ser Gly Ser Gly Ser
Asp Thr Leu 180 185 190 Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile
Ser Arg Asp Asn Ala 195 200 205 Lys Thr Thr Leu Tyr Leu Gln Met Asn
Ser Leu Arg Pro Glu Asp Thr 210 215 220 Ala Val Tyr Tyr Cys Thr Ile
Gly Gly Ser Leu Ser Arg Ser Ser Gln 225 230 235 240 Gly Thr Leu Val
Thr Val Ser Ser Ala 245
* * * * *